WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2023 This List shall come into effect on 1 January 2023. www.wada-ama.org 2 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents................................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics............7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists.................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators................................................................................... 10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods............................................................................................. 13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants........................................................................................................................................... 14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics............................................................................................................................................. 16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries. S8 Cannabinoids.................................................................................................................................... 17 S9 Glucocorticoids............................................................................................................................... 18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers................................................................................................................................... 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX................................................................................................................................................................... 20 TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. 3 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2023. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC). THE 2023 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2023 Published by: World Anti-Doping Agency Stock Exchange Tower 800 Place Victoria (Suite 1700) PO Box 120 Montreal, Quebec Canada H4Z 1B7 URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: code@wada-ama.org 4 S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157. PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. NON-APPROVED SUBSTANCES 5 • 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-hydroxy-DHEA • 7ß-hydroxy-DHEA • 7-Keto-DHEA • 17ɑ-methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro- 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- 17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) • Gestrinone Anabolic agents are prohibited. When administered exogenously, including but not limited to: 1. ANABOLIC ANDROGENIC STEROIDS (AAS) S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 6 S1 • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl- 5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ- methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ- methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy- 17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a- homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) and other substances with a similar chemical structure or similar biological effect(s). 1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. ANABOLIC AGENTS (continued) 7 S2 Including, but not limited to: 1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. 1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. 1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 8 Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. 3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued) 2.1 Chorionic gonadotrophin (CG) and luteinizing hormone (LH) and their releasing factors in males, e.g. buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin 2.2 Corticotrophins and their releasing factors, e.g. corticorelin 2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. lenomorelin (ghrelin), anamorelin, ipamorelin, macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin)] 2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS 9 S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Fenoterol • Formoterol • Higenamine • Indacaterol • Levosalbutamol • Olodaterol • Procaterol • Reproterol • Salbutamol • Salmeterol • Terbutaline • Tretoquinol (trimetoquinol) • Tulobuterol • Vilanterol The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. NOTE • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours. EXCEPTIONS BETA-2 AGONISTS 10 S4 The following hormone and metabolic modulators are prohibited. Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone 4.1. AROMATASE INHIBITORS Including, but not limited to: • Bazedoxifene • Clomifene • Cyclofenil • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene 4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. HORMONE AND METABOLIC MODULATORS 11 Including, but not limited to: • Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab) 4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION 4.4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio) phenoxy) acetic acid (GW1516, GW501516) 4.4.2 Insulins and insulin-mimetics 4.4.3 Meldonium 4.4.4 Trimetazidine 4.4. METABOLIC MODULATORS S4 HORMONE AND METABOLIC MODULATORS (continued) 12 S5 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene and vaptans, e.g. tolvaptan. and other substances with a similar chemical structure or similar biological effect(s). DIURETICS AND MASKING AGENTS The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. NOTE • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. EXCEPTIONS 13 PROHIBITED METHODS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M2. CHEMICAL AND PHYSICAL MANIPULATION The following, with the potential to enhance sport performance, are prohibited: 1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. 2. The use of normal or genetically modified cells. M3. GENE AND CELL DOPING PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. 14 S6 All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. A stimulant not expressly listed in this section is a Specified Substance. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) Stimulants include: • Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex • Fonturacetam [4-phenylpiracetam (carphedon)] • Furfenorex • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane A: NON-SPECIFIED STIMULANTS STIMULANTS 15 S6 Including, but not limited to: • 3-Methylhexan-2-amine (1,2-dimethylpentylamine) • 4-fluoromethylphenidate • 4-Methylhexan-2-amine (methylhexaneamine, 1,3-dimethylamylamine, 1,3 DMAA) • 4-Methylpentan-2-amine (1,3-dimethylbutylamine) • 5-Methylhexan-2-amine (1,4-dimethylpentylamine, 1,4-dimethylamylamine, 1,4-DMAA) • Benzfetamine • Cathine** • Cathinone and its ana- logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone • Dimetamfetamine (dimethylamphetamine) • Ephedrine*** • Epinephrine**** (adrenaline) • Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydrafinil (fluorenol) • Hydroxyamfetamine (parahydroxyamphet- amine) • Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham- phetamine • Methylephedrine*** • Methylnaphthidate [((±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate] • Methylphenidate • Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl- hexylamine) • Octopamine • Oxilofrine (methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine (methylenedioxyamphet- amine) • Tuaminoheptane * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2023 Monitoring Program and are not considered Prohibited Substances. ** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. B: SPECIFIED STIMULANTS • Clonidine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, xylometazoline) and those stimulants included in the 2023 Monitoring Program*. and other substances with a similar chemical structure or similar biological effect(s). STIMULANTS (continued) EXCEPTIONS 16 S7 • Buprenorphine • Dextromoramide • Diamorphine (heroin) • Fentanyl and its derivatives • Hydromorphone • Methadone • Morphine • Nicomorphine • Oxycodone • Oxymorphone • Pentazocine • Pethidine The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) NARCOTICS 17 S8 All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) • Cannabidiol CANNABINOIDS EXCEPTIONS 18 S9 All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort • Dexamethasone • Fluocortolone • Flunisolide • Fluticasone • Hydrocortisone • Methylprednisolone • Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. GLUCOCORTICOIDS • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. NOTE 19 P1 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol • Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol • Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol • Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol *Also prohibited Out-of-Competition PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances. BETA-BLOCKERS 20 INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 15 1-Androstenediol, 5 1-Androstenedione, 5 1-Androsterone, 5 1-Epiandrosterone, 5 1-Testosterone, 5 1,2-Dimethylpentylamine, 15 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5 1,3-Dimethylamylamine (1,3 DMAA), 15 1,3-Dimethylbutylamine, 15 1,4-Dimethylamylamine (1,4-DMAA), 15 1,4-Dimethylpentylamine, 15 1,5- Dimethyl-hexylamine, 15 2-Androstenol, 10 2-Androstenone, 10 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 3ß-Hydroxyandrost-5-en-17-one, 6 3-Androstenol, 10 3-Androstenone, 10 3-Methylhexan-2-amine, 15 4-Androstene-3,6,17 trione, 10 4-Androstenediol, 5 4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 4-Fluoromethylphenidate, 15 4-Hydroxytestosterone, 5 4-Methylhexan-2-amine, 15 4-Methylpentan-2-amine, 15 4-Phenylpiracetam, 14 4,17ß-Dihydroxyandrost-4-en-3-one, 5 5ɑ-Androst-1-ene-3, 17-dione, 5 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 5ɑ-Androst-2-en-17-ol, 10 5ɑ-Androst-2-en-17-one, 10 5ɑ-Androst-3-en-17-ol, 10 5ɑ-Androst-3-en-17-one, 10 5ɑ-Dihydrotestosterone, 5 5-Androstenedione, 5 5-Methylhexan-2-amine, 15 6-Oxo, 10 7ɑ-Hydroxy-DHEA, 5 7ß-Hydroxy-DHEA, 5 7-Keto-DHEA, 5 11-Ketoandrostenedione, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 17ɑ-Methylepithiostanol, 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 17ß-Hydroxy-5ɑ-androstan-3-one, 5 17ß-Hydroxy-5ß-androstan-3-one, 5 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6 17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6 17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6 17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6 19-Norandrostenediol, 5 19-Norandrostenedione, 5 19-Norpregna-4-en-17ɑ-ol, 5 19-Nortestosterone, 6 ɑ-Pyrrolidinovalerophenone, 15 A ACE-031, 11 Acebutolol, 19 Acetazolamide, 12 Activin A-neutralizing antibodies, 11 Activin receptor IIB competitors, 11 Adrafinil, 14 Adrenaline, 15 Adrenosterone, 5 AICAR, 11 Albumin, 12 Alexamorelin, 8 Alprenolol, 19 Amfepramone, 14 Amfetamine, 14 Amfetaminil, 14 Amiloride, 12 Aminoglutethimide, 10 Amiphenazole, 14 AMP-activated protein kinase (AMPK), 11 Anamorelin, 8 Anastrozole, 10 Andarine, 6 Androst-4-ene-3ß,17ß-diol, 5 Androst-4-ene-3,11,17- trione, 5 Androst-4-ene-3,17-dione, 5 Androst-5-ene-3ß,17ß-diol, 5 Androst-5-ene-3,17-dione, 5 Androsta-1,4,6-triene-3,17-dione, 10 Androsta-1,4-diene-3,17-dione, 5 Androsta-3,5-diene-7,17-dione, 10 Androstanolone, 5 Androstatrienedione, 10 Androstenediol, 5 Androstenedione, 5 Anti-activin receptor IIB antibodies, 11 AOD-9604, 7 Apitegromab, 11 Arformoterol, 9 Arimistane, 10 Asialo EPO, 7 Atenolol, 19 B Bazedoxifene, 10 Beclometasone, 18 Bendroflumethiazide, 12 Benfluorex, 14 Benzfetamine, 15 Benzylpiperazine, 14 Betamethasone, 18 Betaxolol, 19 Bimagrumab, 11 Bisoprolol, 19 Blood, 13 Blood (autologous), 13 Blood (components), 13 Blood (heterologous), 13 Blood (homologous), 13 Blood manipulation, 13 Bolasterone, 5 Boldenone, 5 Boldione, 5 BPC-157, 4 Brimonidine, 15 Brinzolamide, 12 21 INDEX Bromantan, 14 Budesonide, 18 Bumetanide, 12 Bunolol, 19 Buprenorphine, 16 Buserelin, 8 C Calusterone, 5 Cannabidiol, 17 Cannabis, 17 Canrenone, 12 Carbamylated EPO (CEPO), 7 Carphedon, 14 Carteolol, 19 Carvedilol, 19 Cathine, 12, 15 Cathinone, 15 Celiprolol, 19 Cell (doping), 13 Cell (genetically modified), 13 Cell (normal), 13 Cell (red blood), 13 Chlorothiazide, 12 Chlortalidone, 12 Chorionic Gonadotrophin (CG), 8 Ciclesonide, 18 CJC-1293, 8 CJC-1295, 8 Clenbuterol, 6 Clobenzorex, 14 Clomifene, 10 Clonazoline, 15 Clonidine, 15 Clostebol, 5 CNTO-530, 7 Cobalt, 7 Cocaine, 14 Corticorelin, 8 Corticotrophins, 8 Cortisone, 18 Cropropamide, 14 Crotetamide, 14 Cyclofenil, 10 D Danazol, 5 Daprodustat, 7 Darbepoetins (dEPO), 7 Deflazacort, 18 Dehydrochlormethyltestosterone, 5 Dehydroepiandrosterone (DHEA), 6 Deslorelin, 8 Desmopressin, 12 Desoxymethyltestosterone, 5 Dexamethasone, 18 Dextran, 12 Dextromoramide, 16 Diamorphine, 16 Dimetamfetamine, 15 Dimethylamphetamine, 15 Domagrozumab, 11 Dorzolamide, 12 Drospirenone, 12 Drostanolone, 5 E Ecstasy, 14 Efaproxiral (RSR13), 13 Enobosarm, 6 Ephedrine, 12, 15 Epiandrosterone, 5 Epi-dihydrotestosterone, 5 Epinephrine, 15 Epistane, 5 Epitestosterone, 5 EPO-based constructs, 7 EPO-Fc, 7 EPO-mimetic agents, 7 Erythropoietin receptor agonists, 7 Erythropoietins (EPO), 7 Esmolol, 19 Estr-4-ene-3,17-diol, 5 Estr-4-ene-3,17-dione, 5 Etacrynic acid, 12 Etamivan, 15 Ethylestrenol, 5 Ethylphenidate, 15 Etilamfetamine, 15 Etilefrine, 15 Examorelin, 8 Exemestane, 10 F Famprofazone, 15 Felypressin, 12 Fenbutrazate, 15 Fencamfamin, 15 Fencamine, 14 Fenetylline, 14 Fenfluramine, 14 Fenoterol, 9 Fenoxazoline, 15 Fenproporex, 14 Fentanyl, 16 Fibroblast growth factors (FGFs), 8 Flunisolide, 18 Fluocortolone, 18 Fluorenol, 15 Fluoxymesterone, 5 Fluticasone, 18 Follistatin, 11 Fonturacetam, 14 Formebolone, 5 Formestane, 10 Formoterol, 9, 12 Fulvestrant, 10 Furazabol, 5 Furfenorex, 14 Furosemide, 12 G GATA inhibitors, 7 Gene doping, 13 Gene editing, 13 Gene silencing, 13 Gene transfer, 13 Gestrinone, 5 Ghrelin, 8 GH-releasing peptides (GHRPs), 8 Gonadorelin, 8 Goserelin, 8 Growth hormone (GH), 8 Growth hormone secretagogues (GHS), 8 GW1516, 11 GW501516, 11 H Haemoglobin (products), 13 Haemoglobin (based blood substitutes), 13 Haemoglobin (microencapsulated products), 13 Hashish, 17 22 INDEX Hepatocyte growth factor (HGF), 8 Heptaminol, 15 Heroin, 16 Hexarelin, 8 hGH 176-191, 8 Higenamine, 9 Hydrafinil, 15 Hydrochlorothiazide, 12 Hydrocortisone, 18 Hydromorphone, 16 Hydroxyamfetamine, 15 Hydroxyethyl starch, 12 Hypoxia-inducible factor (HIF) activating agents, 7 I Imidazoline, 15 Indacaterol, 9 Indanazoline, 15 Indapamide, 12 Infusions, 13 Injections (> 100 mL), 13 Innate repair receptor agonists, 7 Insulin-like growth factor-1 (IGF-1), 8 Insulin-mimetics, 11 Insulins, 11 Intravenous infusions/injections, 13 IOX2, 7 Ipamorelin, 8 Isometheptene, 15 K K-11706, 7 L Labetalol, 19 Landogrozumab, 11 Lenomorelin, 8 Letrozole, 10 Leuprorelin, 8 Levmetamfetamine, 15 Levosalbutamol, 9 LGD-4033, 6 Ligandrol, 6 Lisdexamfetamine, 14 Lonapegsomatropin, 8 Luspatercept, 7 Luteinizing hormone (LH), 8 M Macimorelin, 8 Mannitol, 12 Marijuana, 17 Mechano growth factors (MGFs), 8 Meclofenoxate, 15 Mefenorex, 14 Meldonium, 11 Mephedrone, 15 Mephentermine, 14 Mesocarb, 14 Mestanolone, 6 Mesterolone, 6 Metamfetamine(d-), 14 Metandienone, 6 Metenolone, 6 Methadone, 16 Methandriol, 6 Methasterone, 6 Methedrone, 15 Methoxy polyethylene glycol-epoetin beta (CERA), 7 Methyl-1-testosterone, 6 Methylclostebol, 6 Methyldienolone, 6 Methylenedioxyamphetamine, 15 Methylenedioxymethamphetamine, 15 Methylephedrine, 12, 15 Methylhexaneamine, 15 Methylnaphtidate, 15 Methylnortestosterone, 6 Methylphenidate, 15 Methylprednisolone, 18 Methylsynephrine, 15 Methyltestosterone, 6 Methyltrienolone, 6 Metipranolol, 19 Metolazone, 12 Metoprolol, 19 Metribolone, 6 Mibolerone, 6 Modafinil, 14 Molidustat, 7 Mometasone, 18 Morphine, 16 Myostatin inhibitors, 11 Myostatin precursor-neutralizing antibodies, 11 Myostatin propeptide, 11 Myostatin-binding proteins, 11 Myostatin-neutralizing antibodies, 11 N Nadolol, 19 Nafarelin, 8 Nandrolone, 6 Naphazoline, 15 Nebivolol, 19 Nicomorphine, 16 Nikethamide, 15 Norboletone, 6 Norclostebol, 6 Norethandrolone, 6 Norfenefrine, 15 Norfenfluramine, 14 Nucleic acids, 13 Nucleic acid analogues, 13 O Octodrine, 15 Octopamine, 15 Olodaterol, 9 Osilodrostat, 6 Ospemifene, 10 Ostarine, 6 Oxabolone, 6 Oxandrolone, 6 Oxilofrine, 15 Oxprenolol, 19 Oxycodone, 16 Oxymesterone, 6 Oxymetazoline, 15 Oxymetholone, 6 Oxymorphone, 16 P Pamabrom, 12 Parahydroxyamphetamine, 15 Peginesatide, 7 Pemoline, 15 Pentazocine, 16 Pentetrazol, 15 Perfluorochemicals, 13 Peroxisome proliferator activated receptor delta agonists, 11 Pethidine, 16 Phendimetrazine, 14 Phenethylamine, 15 23 INDEX Phenmetrazine, 15 Phenpromethamine, 15 Phentermine, 14 Pindolol, 19 Plasma expanders, 12 Platelet-derived growth factor (PDGF), 8 p-methylamfetamine, 14 Pralmorelin, 8 Prasterone, 6 Prednisolone, 18 Prednisone, 18 Prenylamine, 14 Probenecid, 12 Procaterol, 9 Prolintane, 14 Propranolol, 19 Propylhexedrine, 15 Prostanozol, 6 Proteases, 13 Pseudoephedrine, 12, 15 Q Quinbolone, 6 R RAD140, 6 Ractopamine, 6 Raloxifene, 10 Reproterol, 9 Roxadustat, 7 S S-23, 6 Salbutamol, 9, 12 Salmeterol, 9 Selective androgen receptor modulators (SARMs), 6 Selegiline, 15 Sermorelin, 8 Sibutramine, 15 Solriamfetol, 15 Somapacitan, 8 Somatrogon, 8 Sotalol, 19 Sotatercept, 7 Spironolactone, 12 SR9009, 11 Stamulumab, 11 Stanozolol, 6 Stenbolone, 6 Strychnine, 15 T Tabimorelin, 8 Tamoxifen, 10 Tampering, 13 TB-500, 8 Tenamfetamine, 15 Terbutaline, 9 Tesamorelin, 8 Testolactone, 10 Testosterone, 6 Tetrahydrocannabinols, 17 Tetrahydrogestrinone, 6 Tetryzoline, 15 Thiazides, 12 Thymosin-ß4, 8 Tibolone, 6 Timolol, 19 Tolvaptan, 12 Torasemide, 12 Toremifene, 10 Transforming growth factor beta (TGF-ß) signalling inhibitors, 7 Trenbolone, 6 Tretoquinol, 9 Triamcinolone acetonide, 18 Triamterene, 12 Trimetazidine, 11 Trimetoquinol, 9 Triptorelin, 8 Tuaminoheptane, 15 Tulobuterol, 9 V Vadadustat (AKB-6548), 7 Vaptans, 12 Vascular endothelial growth factor (VEGF), 8 Vilanterol, 9 Voxelotor, 13 X Xenon, 7 Xylometazoline, 15 Y YK-11, 6 Z Zeranol, 6 Zilpaterol, 6 www.wada-ama.org www.wada-ama.org www.wada-ama.org www.wada-ama.org www.wada-ama.org www.wada-ama.org

list99 INTERNATIONAL OLYMPIC COMMITTEE MEDICAL CODE PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS 31st January 1999 Doping contravenes the ethics of both sport and medical science. Doping consists of: 1. the administration of substances belonging to prohibited classes of pharmacological agents, and/or 2. the use of various prohibited methods. I. PROHIBITED CLASSES OF SUBSTANCES A. Stimulants B. Narcotics C. Anabolic Agents D. Diuretics E. Peptide hormones, mimetics and analogues Hl. PROHIBITED METHODS A. Blood doping B. Pharmacological, chemical and physical manipulation Iii. CLASSES OF DRUGS SUBJECT TO CERTAIN RESTRICTIONS A. Alcohol B. Cannabinoids C. Local anaesthetics D. Corticosteroids E. Beta-blockers list99 I. PROHIBITED CLASSES OF SUBSTANCES Prohibited substances fall into the following classes of substances: A. Stimulants B. Narcotics C. Anabolic Agents D. Diuretics E. Peptide hormones, mimetics and analogues All substances belonging to the prohibited classes cannot be used even if they are not listed as examples. For this reason, the term “and related substances” is introduced. This term describes drugs that are related to the class by their pharmacological action and/or chemical structure. A. Stimulants Prohibited substances in class (A) include the following examples: amineptine, amiphenazole, amphetamines, bromantan, caffeine*, carphedon, cocaine, ephedrines**, fencamfamin, mesocarb, pentetrazol, pipradrol, salbutamol***, salmeterol***, terbutaline***, ... and related substances. * For caffeine the definition of a positive is a concentration in urine greater than 12 micrograms per millilitre. *** For ephedrine, cathine and methylephedrine, the definition of a positive is a concentration in urine greater than 5 micrograms per millilitre. For phenylpropanolamine and pseudoephedrine, the definition of a positive is a concentration in urine greater than 10 micrograms per millilitre. If more than one of these substances are present below their respective thresholds, the concentrations should be added. If the sum is greater than 10 micrograms per millilitre, the sample shall be considered positive. *** Dermitted by inhaler only to prevent and/or treat asthma and exercise-induced asthma. Written notification of asthma and/or exercise-induced asthma by a respiratory or team physician is necessary to the relevant medical authority. NOTE: All imidazole preparations are acceptable for topical use, e.g. oxymetazoline. Vasoconstrictors (e.g. adrenaline) may be administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological) of phenylephrine are permitted. list99 B. Narcotics Prohibited substances in class (B) include the following examples: buprenorphine, dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine, .« and related substances. NOTE: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate, ethylmorphine, pholcodine, propoxyphene and tramadol are permitted. C. Anabolic agents Prohibited substances in class (C) include the following examples: 1. Anabolic androgenic steroids a. clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol, ... and related substances. b. androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone*, ... and related substances. Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definitive conclusions. * The presence of a testosterone (T) to epitestostrone (E) ratio greater than six (6) to one (1) in the urine of a competitor constitutes an offence unless there is evidence that this ratio is due to a physiological or pathological condition, e.g. low epitestosterone excretion, androgen producing tumour, enzyme deficiencies. In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an investigation before the sample is declared positive. A full report will be written and will include a review of previous tests, subsequent tests and any results of endocrine investigations. In the event that previous tests are not available, the athlete should be tested unannounced at least once per month for three months. The results of these investigations should be included in the report. Failure to co-operate in the investigations will result in declaring the sample positive. list99 2, Beta-2 agonists When administered orally or by injection. bambuterol, clenbuterol, fenoterol, formoterol, reproterol, salbutamol”, terbutaline”, .. and related substances. *Permitted by inhalation as described in Article (1.A.). D. Diuretics Prohibited substances in class (D) include the following examples: acetazolamide, bumetanide, chlortalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannitol*, mersalyl, spironolactone, triamterene, ... and related substances. * Prohibited by intravenous injection. E. Peptide hormones. mimetics and analogues Prohibited substances in class (E) include the following examples and their analogues and mimetics: 1. Chorionic Gonadotrophin (hCG); 2. Pituitary and synthetic gonadotrophins (LH); 3. Corticotrophins (ACTH, tetracosactide); 4. Growth hormone (hGH); 5. Insulin-like Growth Factor (IGF-1); and all the respective releasing factors and their analogues; 6. Erythropoietin (EPO); 7. Insulin; permitted only to treat insulin-dependent diabetes. Written notification of insulin-dependent diabetes by an endocrinologist or team physician is necessary. list99 The presence of an abnormal concentration of an endogenous hormone or its diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has been conclusively documented to be solely due to a physiological or pathological condition. II. PROHIBITED METHODS The following procedures are prohibited: Blood doping Blood doping is the administration of blood, red blood cells, artificial oxygen carriers, and related blood products to an athlete. Pharmacological, chemical and physical manipulation Pharmacological, chemical and physical manipulation is the use of substances and of methods which alter, attempt to alter, or may reasonably be expected to alter the integrity and validity of samples used in doping controls. These include, without limitation, the administration of diuretics, catheterisation, sample substitution and or tampering, inhibition of renal excretion such as by probenecid and related compounds, and alterations of testosterone and epitestosterone measurements such as epitestosterone* or bromantan administration. * An epitestosterone concentration in the urine greater than 200 nanograms per millilitre will be investigated by studies as in Article (I.C.1. b.) for testosterone. The success or failure of the use of a prohibited substance or method is not material. It is sufficient that the said substance or procedure was used or attempted for the infraction to be considered as consummated. Ill. CLASSES OF DRUGS SUBJECT TO CERTAIN RESTRICTIONS A, Alcohol Where the rules of a responsible authority so provide, tests will be conducted for ethanol. B. Cannabinoids Where the rules of a responsible authority so provide, tests will be conducted for cannabinoids (e.g. Marijuana, Hashish). At the Olympic Games, tests will be conducted for cannabinoids. A concentration in urine of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (carboxy-THC) greater than 15 nanograms per millilitre is prohibited. list99 C. Local anaesthetics Injectable local anaesthetics are permitted under the following conditions: a. bupivacaine, lidocaine, mepivacaine, procaine, etc. can be used but not cocaine. Vasoconstrictor agents (e.g. adrenaline) may be used in conjunction with local anaesthetics. only local or intra-articular injections may be administered; c. only when medically justified. Where the rules of a responsible authority so provide, notification of administration may be necessary. D. Corticosteroids The systemic use of corticosteroids is prohibited. Anal, aural, dermatological, inhalational, nasal and ophthalmological (but not rectal) administration is permitted. Intra-articular and local injections of corticosteroids are permitted. Where the rules of a responsible authority so provide, notification of administration may be necessary. E. Beta-blockers Some examples of beta-blockers are: acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol, .. and related substances. Where the rules of an International Sports Federation so provide, tests will be conducted for beta-blockers. list99 SUMMARY OF IOC REGULATIONS FOR DRUGS WHICH NEED THE WRITTEN NOTIFICATION OF A PHYSICIAN beta-agonists* ~ Systemic injections PERMITTED PERMITTED SUBSTANCES PROHIBITED WITH WITHOUT NOTIFICATION NOTIFICATION Selected - Oral - Inhalational Corticosteroids - Oral - Systemic injections - Rectal anal, aural, dermatological, inhalational, nasal, ophthalmological, -local and intra-articular injections *** Local anaesthetics** - Systemic injections local and intra-articular injections *** * — Salbutamol, salmeterol, terbutaline; all other beta-agonists are prohibited. ** Except cocaine, which ts prohibited. *** Where the rules of the responsible authority so provide, notification may be necessary. SUMMARY OF URINARY CONCENTRATIONS ABOVE WHICH IOC ACCREDITED LABORATORIES MUST REPORT FINDINGS FOR SPECIFIC SUBSTANCES caffeine > 12 micrograms/millilitre carboxy-THC > 15 nanograms/millilitre cathine > 5 micrograms / milliltre ephedrine > 5 micrograms / milliltre epitestosterone > 200 nanograms / millilitre methylephedrine > 5 micrograms / millilitre morphine > |] microgram / millilitre phenylpropanolamine > 10 micrograms / millilitre pseudoephedrine > 10 micrograms / millilitre T/E ratio > 6 7 list99 LIST OF EXAMPLES OF PROHIBITED SUBSTANCES CAUTION: This is not an exhaustive list of prohibited substances. Many substances that do not appear on this list are considered prohibited under the term "and related substances". All athletes are strongly advised only to take medicines which are prescribed by a medical doctor and to ensure that they contain only drugs that are not prohibited by the IOC Medical Commission or the responsible authorities. Whenever an athlete is required to undergo a doping control all medications and drugs taken or administered in the previous seven days should be declared on the doping control official record. STIMULANTS: amineptine, amfepramone, amiphenazole, amphetamine, bambuterol, bromantan, caffeine, carphedon, cathine, cocaine, cropropamide, crotethamide, ephedrine, etamivan, etilamphetamine, _ etilefrine, fencamfamin, fenetylline, fenfluramine, formoterol, heptaminol, mefenorex, mephentermine, mesocarb, methamphetamine, methoxyphenamine, methylenedioxyamphetamine, methylephedrine, methylphenidate, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phentermine, phenylephrine, phenylpropanolamine, pholedrine, pipradrol, prolintane, propylhexedrine, pseudoephedrine, reproterol, salbutamol, salmeterol, selegiline, strychnine, terbutaline, NARCOTICS: buprenorphine, dextromoramide, diamorphine (heroin), hydrocodone, methadone, morphine, pentazocine, pethidine, ANABOLIC AGENTS : androstenediol, androstenedione, bambuterol, boldenone, clenbuterol, clostebol, danazol, dehydrochlormethyltestosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone, drostanolone, fenoterol, fluoxymesterone, formebolone, formoterol, gestrinone, mesterolone, metandienone, metenolone, methandriol, methyltestosterone, mibolerone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, norethandrolone, oxandrolone, oxymesterone, oxymetholone, reproterol, salbutamol, salmeterol, stanozolol, terbutaline, testosterone, trenbolone, list99 DIURETICS acetazolamide, bendroflumethiazide, bumetanide, canrenone, chlortalidone, ethacrynic acid, furosemide, hydrochlorothiazide, indapamide, mannitol, mersalyl, spironolactone, triamterene, MASKING AGENTS bromantan, diuretics (see above), epitestosterone, probenecid, PEPTIDE HORMONES, MIMETICS AND ANALOGUES ACTH, erythropoietin (EPO), hCG, hGH. insulin, LH, BETA BLOCKERS acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol.

1 SUBSTITUTES APPENDIX A OF THE OMAC 1999 OLYMPIC MOVEMENT ANTI-DOPING CODE APPENDIX A PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS 2001-2002 1 September 2001 I. PROHIBITED CLASSES OF SUBSTANCES A. Stimulants Prohibited substances in class (A) include the following examples: amineptine, amiphenazole, amphetamines, bromantan, caffeine*, carphedon, cocaine, ephedrines**,fencamfamin, formoterol ***, mesocarb, pentetrazol, pipradrol, salbutamol***, salmeterol***, terbutaline***, ... and related substances. * For caffeine the definition of a positive is a concentration in urine greater than 12 micrograms per millilitre. ** For cathine, the definition of a positive is a concentration in urine greater than 5 micrograms per millilitre. For ephedrine and methylephedrine, the definition of a positive is a concentration in urine greater than 10 micrograms per millilitre. For phenylpropanolamine and pseudoephedrine, the definition of a positive is a concentration in urine greater than 25 micrograms per millilitre. *** Permitted by inhaler only to prevent and/or treat asthma and exercise-induced asthma.. Written notification by a respiratory or team physician that the athlete has asthma and/or exercise-induced asthma, is necessary to the relevant medical authority prior to competition.. At the Olympics Games, athletes who request permission to inhale a permitted beta agonist will be assessed by an independent medical panel. NOTE: All imidazole preparations are acceptable for topical use. Vasoconstrictors may be administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological, rectal) of adrenaline and phenylephrine are permitted. B. Narcotics Prohibited substances in class (B) include the following examples: 2 buprenorphine, dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine, ... and related substances. NOTE: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate, ethylmorphine, pholcodine, propoxyphene and tramadol are permitted. C. Anabolic agents Prohibited substances in class (C) include the following examples: 1. Anabolic androgenic steroids a. clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol, ... and related substances. b. androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone*, ... and related substances. Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definitive conclusions. * The presence of a testosterone (T) to epitestostrone (E) ratio greater than six (6) to one (1) in the urine of a competitor constitutes an offence unless there is evidence that this ratio is due to a physiological or pathological condition, e.g. low epitestosterone excretion, androgen producing tumour, enzyme deficiencies. In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an investigation before the sample is declared positive. A full report will be written and will include a review of previous tests, subsequent tests and any results of endocrine investigations. In the event that previous tests are not available, the athlete should be tested unannounced at least once per month for three months. The results of these investigations should be included in the report. Failure to co-operate in the investigations will result in declaring the sample positive. 2. Beta-2 agonists 3 bambuterol, clenbuterol, fenoterol, formoterol*, reproterol, salbutamol*, salmeterol*, terbutaline*, ... and related substances. *Authorized by inhalation as described in Article (I.A.). For salbutamol the definition of a positive under the anabolic agent category is a concentration in urine greater than 1000 nanograms per millilitre. D. Diuretics Prohibited substances in class (D) include the following examples: acetazolamide, bumetanide, chlortalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannitol*, mersalyl, spironolactone, triamterene, ... and related substances. * Prohibited by intravenous injection. E. Peptide hormones, mimetics and analogues Prohibited substances in class (E) include the following examples and their analogues and mimetics: 1. Chorionic Gonadotrophin (hCG) prohibited in males only; 2. Pituitary and synthetic gonadotrophins (LH) prohibited in males only; 3. Corticotrophins (ACTH, tetracosactide); 4. Growth hormone (hGH); 5. Insulin-like Growth Factor (IGF-1); and all the respective releasing factors and their analogues; 6. Erythropoietin (EPO); 7. Insulin; permitted only to treat athletes with certified insulin-dependent diabetes. Written certification of insulin-dependent diabetes must be obtained from an endocrinologist or team physician. The presence of an abnormal concentration of an endogenous hormone in class (E)or its diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has been proven to be due to a physiological or pathological condition. II. PROHIBITED METHODS 4 The following procedures are prohibited: 1. Blood doping : means the administration of blood, red blood cells and/or related blood products to an athlete, which may be preceded by withdrawal of blood from the athlete, who continues to train in such a blood-depleted state. 2 Administering artificial oxygen carriers or plasma expanders; 3. Pharmacological, chemical and physical manipulation. III. CLASSES OF PROHIBITED SUBSTANCES IN CERTAIN CIRCUMSTANCES A. Alcohol Where the rules of a responsible authority so provide, tests will be conducted for ethanol. B. Cannabinoids Where the rules of a responsible authority so provide, tests will be conducted for cannabinoids (e.g. Marijuana, Hashish). At the Olympic Games, tests will be conducted for cannabinoids. A concentration in urine of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (carboxy-THC) greater than 15 nanograms per millilitre constitutes doping. C. Local anaesthetics Injectable local anaesthetics are permitted under the following conditions: a. bupivacaine, lidocaine, mepivacaine, procaine, and related substances, can be used but not cocaine. Vasoconstrictor agents may be used in conjunction with local anaesthetics; b. only local or intra-articular injections may be administered; c. only when medically justified. Where the rules of a responsible authority so provide, notification of administration may be necessary. D. Glucocorticosteroids The systemic use of glucocorticosteroids is prohibited when administered orally, rectally, or by intravenous or intramuscular injection. When medically necessary, local and intra-articular injections of glucocorticosteroids are permitted. Where the rules of a responsible medical authority so provide, notification of administration may be necessary. 5 E. Beta-blockers Prohibited substances in class (E) include the following examples: acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol, ... and related substances. Where the rules of a responsible authority so provide, tests will be conducted for beta-blockers. SUMMARY OF URINARY CONCENTRATIONS ABOVE WHICH IOC ACCREDITED LABORATORIES MUST REPORT FINDINGS FOR SPECIFIC SUBSTANCES caffeine > 12 micrograms/millilitre carboxy-THC > 15 nanograms/millilitre cathine > 5 micrograms / milliltre ephedrine > 10 micrograms / milliltre epitestosterone > 200 nanograms / millilitre methylephedrine > 10 micrograms / millilitre morphine > 1 microgram / millilitre 19-norandrosterone > 2 nanograms /millilitre in males 19-norandrosterone > 5 nanograms/millilitre in females phenylpropanolamine > 25 micrograms / millilitre pseudoephedrine > 25 micrograms / millilitre salbutamol (as stimulant) > 100 nanograms/millilitre (as anabolic agent) > 1000 nanograms/millilitre T/E ratio > 6 IV. OUT-OF-COMPETITION TESTING 6 Unless specifically requested by the responsible authority, out-of-competition testing is directed solely at prohibited substances in class I.C. (Anabolic Agents), I.D. (Diuretics), I.E. (Peptide Hormones, Mimetics and Analogues), and II (Prohibited Methods). LIST OF EXAMPLES OF PROHIBITED SUBSTANCES AND PROHIBITED METHODS CAUTION: This is not an exhaustive list of prohibited substances. Many substances that do not appear on this list are considered prohibited under the term "and related substances". Athletes must ensure that any medicine, supplement, over-the-counter preparation or any other substance they use does not contain any Prohibited Substance. STIMULANTS: amineptine, amfepramone, amiphenazole, amphetamine, bambuterol, bromantan, bupropion, caffeine, carphedon, cathine, cocaine, cropropamide, crotethamide, ephedrine, etamivan, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, formoterol, heptaminol, mefenorex, mephentermine, mesocarb, methamphetamine, methoxyphenamine, methylenedioxyamphetamine, methylephedrine, methylphenidate, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phentermine, phenylephrine, phenylpropanolamine, pholedrine, pipradrol, prolintane, propylhexedrine, pseudoephedrine, reproterol, salbutamol, salmeterol, selegiline, strychnine, terbutaline, NARCOTICS: buprenorphine, dextromoramide, diamorphine (heroin), hydrocodone, methadone, morphine, pentazocine, pethidine, 7 ANABOLIC AGENTS : androstenediol, androstenedione, bambuterol, boldenone, clenbuterol, clostebol, danazol, dehydrochlormethyltestosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone, drostanolone, fenoterol, fluoxymesterone, formebolone, formoterol, gestrinone, mesterolone, metandienone, metenolone, methandriol, methyltestosterone, mibolerone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, norethandrolone, oxandrolone, oxymesterone, oxymetholone, reproterol, salbutamol, salmeterol, stanozolol, terbutaline, testosterone, trenbolone, DIURETICS acetazolamide, bendroflumethiazide, bumetanide, canrenone, chlortalidone, ethacrynic acid, furosemide, hydrochlorothiazide, indapamide, mannitol (by intravenous injection), mersalyl, spironolactone, triamterene, MASKING AGENTS bromantan, diuretics (see above), epitestosterone, probenecid, PEPTIDE HORMONES, MIMETICS AND ANALOGUES ACTH, erythropoietin (EPO), hCG*, hGH, insulin, LH*, clomiphene*, cyclofenil*, tamoxifen*, aromatase inhibitors* * prohibited in males only BETA BLOCKERS acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

SUBSTITUTES APPENDIX A OF THE OMAC 1999 OLYMPIC MOVEMENT ANTI-DOPING CODE APPENDIX A PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS 2003 1 January 2003 I. PROHIBITED CLASSES OF SUBSTANCES A. STIMULANTS a Prohibited substances in class A.a include the following examples with both their L- and D-isomers amiphenazole, amphetamines, bromantan, caffeine*, carphedon, cocaine, ephedrines**, fencamfamin, mesocarb, pentetrazol, pipradrol, ... and related substances. * For caffeine the definition of a positive is a concentration in urine greater than 12 micrograms per millilitre. ** For ephedrine and methylephedrine, the definition of a positive is a concentration in urine greater than 10 micrograms per millilitre. For cathine, the definition of a positive is a concentration in urine greater than 5 micrograms per millilitre. For phenylpropanolamine and pseudoephedrine, the definition of a positive is a concentration in urine greater than 25 micrograms per millilitre. NOTE: All imidazole preparations are acceptable for topical use. Vasoconstrictors may be administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological, rectal) of adrenaline are permitted. Bupropion, synephrine and phenylephrine are permitted b Prohibited substances in class A.b include the following examples with both their L- and D-isomers formoterol***, salbutamol***, salmeterol*** and terbutaline*** … and related substances 27 September 2002 1 *** permitted by inhaler only to prevent and/or treat asthma and exercise-induced asthma. Written notification by a respiratory or team physician that the athlete has asthma and/or exercise-induced asthma is necessary to the relevant medical authority prior to competition. At the Olympics Games, athletes who request permission to inhale a permitted beta-2 agonist, will be assessed by an independent medical panel. B. NARCOTICS Prohibited substances in class (B) include the following examples: buprenorphine, dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine,... and related substances. NOTE: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate, ethylmorphine, pholcodine, propoxyphene and tramadol are permitted. C. ANABOLIC AGENTS Prohibited substances in class (C) include the following examples: 1. Anabolic androgenic steroids a. clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol, ... and related substances. b. androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone*, ... and related substances. Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definitive conclusions. * The presence of a testosterone (T) to epitestostrone (E) ratio greater than six (6) to one (1) in the urine of a competitor constitutes an offence unless there is evidence that this ratio is due to a physiological or pathological condition, e.g. low epitestosterone excretion, androgen producing tumour, enzyme deficiencies. In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an investigation before the sample is declared positive. A full report will be written and will include a review of previous tests, subsequent tests and any results of endocrine investigations. In the event that previous tests are not 27 September 2002 2 available, the athlete should be tested unannounced at least once per month for three months. The results of these investigations should be included in the report. Failure to co-operate in the investigations will result in declaring the sample positive. 2. Other anabolic agents clenbuterol, salbutamol * * For salbutamol, a concentration in urine greater than 1000 nanograms per millilitre of non-sulphated salbutamol constitutes a doping violation. D. DIURETICS Prohibited substances in class (D) include the following examples: acetazolamide, bumetanide, chlortalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannitol*, mersalyl, spironolactone, triamterene, ... and related substances. * Prohibited by intravenous injection. E. PEPTIDE HORMONES, MIMETICS AND ANALOGUES Prohibited substances in class (E) include the following examples and their analogues and mimetics: 1. Chorionic Gonadotrophin (hCG) prohibited in males only; 2. Pituitary and synthetic gonadotrophins (LH) prohibited in males only; 3. Corticotrophins(ACTH, tetracosactide); 4. Growth hormone (hGH); 5. Insulin-like Growth Factor (IGF-1); and all the respective releasing factors and their analogues; 6. Erythropoietin (EPO); 7. Insulin* *permitted only to treat athletes with certified insulin-dependent diabetes. The term ‘insulin-dependent’ is used here to describe people with diabetes in whom insulin treatment is required, in the judgement of a suitably qualified physician. It will always be the case in Type 1 and sometimes in Type 2 diabetes mellitus. Written certification of insulin-dependent diabetes must be obtained from an endocrinologist or team physician. The presence of an abnormal concentration of an endogenous hormone in class (E) or its diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has been proven to be due to a physiological or pathological condition. 27 September 2002 3 F. AGENTS WITH ANTI-OESTROGENIC ACTIVITY Aromatase inhibitors, clomiphene, cyclofenil, tamoxifen are prohibited only in males. G. MASKING AGENTS Prohibited substances in class (G) include the following examples: diuretics, epitestosterone*, probenecid, plasma expanders (e.g . hydroxyethyl starch) Masking agents are prohibited. They are products that have the potential to impair the excretion of prohibited substances or to conceal their presence in urine or other samples used in doping control. * The presence of a urinary concentration of epitestosterone greater than 200 ng/mL constitutes an anti-doping violation unless there is evidence that it is due to a physiological condition. Isotopic ratio mass spectrometry (IRMS) may be used to draw definitive conclusions. If the results of the IRMS are inconclusive, the relevant medical authority shall conduct an investigation before the sample is declared positive. II. PROHIBITED METHODS The following procedures are prohibited: A. ENHANCEMENT OF OXYGEN TRANSFER a. Blood doping. Blood doping is the administration of autologous, homologous or heterologous blood or red blood cell products of any origin, other than for legitimate medical treatment. b. The administration of products that enhance the uptake, transport or delivery of oxygen, e.g. modified haemoglobin products including but not limited to bovine and cross-linked haemoglobins, microencapsulated haemoglobin products, perfluorochemicals, and RSR13. 27 September 2002 4 B. PHARMACOLOGICAL, CHEMICAL AND PHYSICAL MANIPULATION Pharmacological, chemical and physical manipulation is the use of substances and methods, including masking agents (ref I . G), which alter, attempt to alter or may reasonably be expected to alter the integrity and validity of specimens collected in doping controls. These include, without limitation, catheterisation, urine substitution and/or tampering, inhibition of renal excretion and alterations of testosterone and epitestosterone (ref I. G) measurements. C. GENE DOPING Gene or cell doping is defined as the non-therapeutic use of genes, genetic elements and/or cells that have the capacity to enhance athletic performance. III. CLASSES OF PROHIBITED SUBSTANCES IN CERTAIN SPORTS A. ALCOHOL Where the rules of the governing body so provide, tests will be conducted for ethanol. B. CANNABINOIDS Where the rules of the governing body so provide, tests will be conducted for cannabinoids (e.g. Marijuana, Hashish). At the Olympic Games, tests will be conducted for cannabinoids. A concentration in urine of 11-nor-delta 9- tetrahydrocannabinol-9-carboxylic acid (carboxy-THC) greater than 15 nanograms per millilitre constitutes doping. C. LOCAL ANAESTHETICS Injectable local anaesthetics are permitted under the following conditions: a. bupivacaine, lidocaine, mepivacaine, procaine, and related substances, can be used but not cocaine. Vasoconstrictor agents may be used in conjunction with local anaesthetics; b. only local or intra-articular injections may be administered; c. only when medically justified. Where the rules of the governing body so provide, notification of administration may be necessary. 27 September 2002 5 D. GLUCOCORTICOSTEROIDS The systemic use of glucocorticosteroids is prohibited when administered orally, rectally, or by intravenous or intramuscular injection. When medically necessary, local and intra-articular injections of glucocorticosteroids are permitted. Where the rules of the governing body so provide, notification of administration may be necessary E. BETA-BLOCKERS Prohibited substances in class (E) include the following examples: acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol, ... and related substances. Where the rules of the governing body so provide, tests will be conducted for beta- blockers. IV. SUMMARY OF URINARY CONCENTRATIONS ABOVE WHICH A DOPING VIOLATION HAS OCCURED caffeine > 12 micrograms/millilitre carboxy-THC > 15 nanograms/millilitre cathine > 5 micrograms / milliltre ephedrine > 10 micrograms / milliltre epitestosterone* > 200 nanograms / millilitre methylephedrine > 10 micrograms / millilitre morphine > 1 microgram / millilitre 19-norandrosterone > 2 nanograms /millilitre in males 19-norandrosterone > 5 nanograms/millilitre in females phenylpropanolamine > 25 micrograms / millilitre pseudoephedrine > 25 micrograms / millilitre salbutamol (as anabolic agent) > 1000 nanograms/millilitre T/E ratio* > 6 * referred to I.C.b and I.G. 27 September 2002 6 V. SUBSTANCES AND METHODS PROHIBITED OUT-OF- COMPETITION I.C. Anabolic Agents I.D. Diuretics I.E. Peptide Hormones, Mimetics and Analogues I.F. Agents with Anti-Oestrogenic Activity I.G. Masking Agents II. Prohibited Methods LIST OF EXAMPLES OF PROHIBITED SUBSTANCES AND PROHIBITED METHODS CAUTION: This is not an exhaustive list of prohibited substances. Many substances that do not appear on this list are considered prohibited under the term "and related substances". Athletes must ensure that any medicine, supplement, over-the-counter preparation or any other substance they use does not contain any Prohibited Substance. STIMULANTS: amfepramone, amiphenazole, amphetamine, bambuterol, bromantan, caffeine, carphedon, cathine, clobenzorex, cocaine, cropropamide, crotethamide, ephedrine, etamivan, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, fenproporex, formoterol, heptaminol, mefenorex, mephentermine, mesocarb, methamphetamine, methoxyphenamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, methylephedrine, methylphenidate, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phentermine, phenmetrazine, phenylpropanolamine, pholedrine, pipradrol, prolintane, propylhexedrine, pseudoephedrine, reproterol, salbutamol, salmeterol, selegiline, strychnine, terbutaline. NARCOTICS: buprenorphine, dextromoramide, diamorphine (heroin), hydrocodone, methadone, morphine, pentazocine, pethidine. 27 September 2002 7 ANABOLIC AGENTS : androstenediol, androstenedione, bambuterol, bolasterone, boldenone, clenbuterol, clostebol, danazol, dehydrochlormethyltestosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone, drostanolone, fenoterol, fluoxymesterone, formebolone, formoterol, gestrinone, mesterolone, metandienone, metenolone, methandriol, methyltestosterone, mibolerone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, norbolethone, norethandrolone, oxandrolone, oxymesterone, oxymetholone, reproterol, salbutamol, salmeterol, stanozolol, terbutaline, testosterone, trenbolone. DIURETICS amiloride, acetazolamide, bendroflumethiazide, bumetanide, canrenone, chlortalidone, ethacrynic acid, furosemide, hydrochlorothiazide, indapamide, mannitol (by intravenous injection), mersalyl, spironolactone, triamterene. MASKING AGENTS diuretics (see above), epitestosterone, probenecid, hydroxy ethyl starch. PEPTIDE HORMONES, MIMETICS AND ANALOGUES ACTH, erythropoietin (EPO), hCG*, hGH, insulin, LH*, IGF-1. SUBSTANCES WITH ANTIOESTREOGENIC ACTIVITY clomiphene*, cyclofenil*, tamoxifen*. * prohibited in males only BETA BLOCKERS acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. 27 September 2002 8

1 SUBSTITUTES APPENDIX A OF THE OMAC 1999 OLYMPIC MOVEMENT ANTI-DOPING CODE APPENDIX A PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS 1st April 2000 I. PROHIBITED CLASSES OF SUBSTANCES A. Stimulants Prohibited substances in class (A) include the following examples: amineptine, amiphenazole, amphetamines, bromantan, caffeine*, carphedon, cocaine, ephedrines**, fencamfamin, mesocarb, pentetrazol, pipradrol, salbutamol***, salmeterol***, terbutaline***, ... and related substances. * For caffeine the definition of a positive is a concentration in urine greater than 12 micrograms per millilitre. ** For cathine, the definition of a positive is a concentration in urine greater than 5 micrograms per millilitre. For ephedrine and methylephedrine, the definition of a positive is a concentration in urine greater than 10 micrograms per millilitre. For phenylpropanolamine and pseudoephedrine, the definition of a positive is a concentration in urine greater than 25 micrograms per millilitre. *** Permitted by inhaler only to prevent and/or treat asthma and exercise-induced asthma. Written notification of asthma and/or exercise-induced asthma by a respiratory or team physician is necessary to the relevant medical authority. NOTE: All imidazole preparations are acceptable for topical use. Vasoconstrictors may be administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological, rectal) of adrenaline and phenylephrine are permitted. B. Narcotics Prohibited substances in class (B) include the following examples: buprenorphine, dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine, ... and related substances. NOTE: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate, ethylmorphine, pholcodine, propoxyphene and tramadol are permitted. 2 C. Anabolic agents Prohibited substances in class (C) include the following examples: 1. Anabolic androgenic steroids a. clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol, ... and related substances. b. androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone*, ... and related substances. Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definitive conclusions. * The presence of a testosterone (T) to epitestostrone (E) ratio greater than six (6) to one (1) in the urine of a competitor constitutes an offence unless there is evidence that this ratio is due to a physiological or pathological condition, e.g. low epitestosterone excretion, androgen producing tumour, enzyme deficiencies. In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an investigation before the sample is declared positive. A full report will be written and will include a review of previous tests, subsequent tests and any results of endocrine investigations. In the event that previous tests are not available, the athlete should be tested unannounced at least once per month for three months. The results of these investigations should be included in the report. Failure to co-operate in the investigations will result in declaring the sample positive. 2. Beta-2 agonists bambuterol, clenbuterol, fenoterol, formoterol, reproterol, salbutamol*, salmeterol*, terbutaline*, ... and related substances. *Authorized by inhalation as described in Article (I.A.). For salbutamol the definition of a positive under the anabolic agent category is a concentration in urine greater than 1000 nanograms per millilitre. 3 D. Diuretics Prohibited substances in class (D) include the following examples: acetazolamide, bumetanide, chlortalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannitol*, mersalyl, spironolactone, triamterene, ... and related substances. * Prohibited by intravenous injection. E. Peptide hormones, mimetics and analogues Prohibited substances in class (E) include the following examples and their analogues and mimetics: 1. Chorionic Gonadotrophin (hCG) prohibited in males only; 2. Pituitary and synthetic gonadotrophins (LH) prohibited in males only; 3. Corticotrophins (ACTH, tetracosactide); 4. Growth hormone (hGH); 5. Insulin-like Growth Factor (IGF-1); and all the respective releasing factors and their analogues; 6. Erythropoietin (EPO); 7. Insulin; permitted only to treat athletes with certified insulin-dependent diabetes. Written certification of insulin-dependent diabetes must be obtained from an endocrinologist or team physician. The presence of an abnormal concentration of an endogenous hormone in class (E)or its diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has been proven to be due to a physiological or pathological condition. II. PROHIBITED METHODS The following procedures are prohibited: 1. Blood doping; 2. Administering artificial oxygen carriers or plasma expanders; 3. Pharmacological, chemical and physical manipulation. 4 III. CLASSES OF PROHIBITED SUBSTANCES IN CERTAIN CIRCUMSTANCES A. Alcohol Where the rules of a responsible authority so provide, tests will be conducted for ethanol. B. Cannabinoids Where the rules of a responsible authority so provide, tests will be conducted for cannabinoids (e.g. Marijuana, Hashish). At the Olympic Games, tests will be conducted for cannabinoids. A concentration in urine of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (carboxy-THC) greater than 15 nanograms per millilitre constitutes doping. C. Local anaesthetics Injectable local anaesthetics are permitted under the following conditions: a. bupivacaine, lidocaine, mepivacaine, procaine, and related substances, can be used but not cocaine. Vasoconstrictor agents may be used in conjunction with local anaesthetics; b. only local or intra-articular injections may be administered; c. only when medically justified. Where the rules of a responsible authority so provide, notification of administration may be necessary. D. Glucocorticosteroids The systemic use of glucocorticosteroids is prohibited when administered orally, rectally, or by intravenous or intramuscular injection. E. Beta-blockers Prohibited substances in class (E) include the following examples: acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol, ... and related substances. Where the rules of a responsible authority so provide, tests will be conducted for beta-blockers. SUMMARY OF URINARY CONCENTRATIONS ABOVE WHICH IOC ACCREDITED LABORATORIES 5 MUST REPORT FINDINGS FOR SPECIFIC SUBSTANCES caffeine > 12 micrograms/millilitre carboxy-THC > 15 nanograms/millilitre cathine > 5 micrograms / milliltre ephedrine > 10 micrograms / milliltre epitestosterone > 200 nanograms / millilitre methylephedrine > 10 micrograms / millilitre morphine > 1 microgram / millilitre 19-norandrosterone > 2 nanograms /millilitre in males 19-norandrosterone > 5 nanograms/millilitre in females phenylpropanolamine > 25 micrograms / millilitre pseudoephedrine > 25 micrograms / millilitre salbutamol (as stimulant) > 100 nanograms/millilitre (as anabolic agent) > 1000 nanograms/millilitre T/E ratio > 6 IV. OUT-OF-COMPETITION TESTING Unless specifically requested by the responsible authority, out-of-competition testing is directed solely at prohibited substances in class I.C. (Anabolic Agents), I.D. (Diuretics), I.E. (Peptide Hormones, Mimetics and Analogues), and II (Prohibited Methods). LIST OF EXAMPLES OF PROHIBITED SUBSTANCES 6 CAUTION: This is not an exhaustive list of prohibited substances. Many substances that do not appear on this list are considered prohibited under the term "and related substances". Athletes must ensure that any medicine, supplement, over-the-counter preparation or any other substance they use does not contain any Prohibited Substance. STIMULANTS: amineptine, amfepramone, amiphenazole, amphetamine, bambuterol, bromantan, caffeine, carphedon, cathine, cocaine, cropropamide, crotethamide, ephedrine, etamivan, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, formoterol, heptaminol, mefenorex, mephentermine, mesocarb, methamphetamine, methoxyphenamine, methylenedioxyamphetamine, methylephedrine, methylphenidate, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phentermine, phenylephrine, phenylpropanolamine, pholedrine, pipradrol, prolintane, propylhexedrine, pseudoephedrine, reproterol, salbutamol, salmeterol, selegiline, strychnine, terbutaline, NARCOTICS: buprenorphine, dextromoramide, diamorphine (heroin), hydrocodone, methadone, morphine, pentazocine, pethidine, ANABOLIC AGENTS : androstenediol, androstenedione, bambuterol, boldenone, clenbuterol, clostebol, danazol, dehydrochlormethyltestosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone, drostanolone, fenoterol, fluoxymesterone, formebolone, formoterol, gestrinone, mesterolone, metandienone, metenolone, methandriol, methyltestosterone, mibolerone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, norethandrolone, oxandrolone, oxymesterone, oxymetholone, reproterol, salbutamol, salmeterol, stanozolol, terbutaline, testosterone, trenbolone, DIURETICS acetazolamide, bendroflumethiazide, bumetanide, canrenone, chlortalidone, ethacrynic acid, furosemide, hydrochlorothiazide, indapamide, mannitol (by intravenous injection), mersalyl, spironolactone, triamterene, MASKING AGENTS bromantan, diuretics (see above), epitestosterone, probenecid, PEPTIDE HORMONES, MIMETICS AND ANALOGUES 7 ACTH, erythropoietin (EPO), hCG*, hGH, insulin, LH*, clomiphene*, cyclofenil*, tamoxifen*, * prohibited in males only BETA BLOCKERS acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2024 This List shall come into effect on 1 January 2024. https://www.wada-ama.org/en 2 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents................................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics............7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists.................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators...................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods............................................................................................. 13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants........................................................................................................................................... 14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics............................................................................................................................................. 16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries. S8 Cannabinoids.................................................................................................................................... 17 S9 Glucocorticoids............................................................................................................................... 18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers................................................................................................................................... 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX...................................................................................................................................................................20 TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. 3 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2024. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC). THE 2024 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2024 Published by: World Anti-Doping Agency Stock Exchange Tower 800 Place Victoria (Suite 1700) PO Box 120 Montreal, Quebec Canada H4Z 1B7 URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: code@wada-ama.org 4 S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157, 2,4- Dinitrophenol (DNP) and Troponin Activators (e.g. Reldesemtiv and Tirasemtiv). PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. NON-APPROVED SUBSTANCES 5 • 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-Hydroxy-DHEA • 7ß-Hydroxy-DHEA • 7-Keto-DHEA • 11ß-Methyl-19-nortestosterone • 17ɑ-Methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro- 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol) • Dimethandrolone (7ɑ,11ß-Dimethyl-19- nortestosterone) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- 17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) Anabolic agents are prohibited. When administered exogenously, including but not limited to: S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 6 S1 • Gestrinone • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl- 5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ- methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ- methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy- 17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a- homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) • Trestolone (7ɑ-Methyl-19-nortestosterone, MENT) and other substances with a similar chemical structure or similar biological effect(s). S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) S1.2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. ANABOLIC AGENTS (continued) 7 S2 Including, but not limited to: S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 8 Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued) S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG), • luteinizing hormone (LH), • gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6] S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS 9 S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Fenoterol • Formoterol • Higenamine • Indacaterol • Levosalbutamol • Olodaterol • Procaterol • Reproterol • Salbutamol • Salmeterol • Terbutaline • Tretoquinol (trimetoquinol) • Tulobuterol • Vilanterol The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. NOTE • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours. EXCEPTIONS BETA-2 AGONISTS 10 S4 The following hormone and metabolic modulators are prohibited. Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone S4.1. AROMATASE INHIBITORS Including, but not limited to: • Bazedoxifene • Clomifene • Cyclofenil • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. HORMONE AND METABOLIC MODULATORS 11 Including, but not limited to: • Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab) S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION S4.4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio) phenoxy) acetic acid (GW1516, GW501516) and Rev-erbɑ agonists, e.g. SR9009, SR9011 S4.4.2 Insulins and insulin-mimetics S4.4.3 Meldonium S4.4.4 Trimetazidine S4.4. METABOLIC MODULATORS S4 HORMONE AND METABOLIC MODULATORS (continued) 12 S5 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan; • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol; • Desmopressin; • Probenecid; and other substances with a similar chemical structure or similar biological effect(s). DIURETICS AND MASKING AGENTS The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. NOTE • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. EXCEPTIONS 13 PROHIBITED METHODS The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system except donation by Athletes of plasma or plasma components by plasmapheresis performed in a registered collection center. M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M2. CHEMICAL AND PHYSICAL MANIPULATION The following, with the potential to enhance sport performance, are prohibited: M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. M3.2. The use of normal or genetically modified cells. M3. GENE AND CELL DOPING PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. 14 S6 All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. A stimulant not expressly listed in this section is a Specified Substance. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) Stimulants include: • Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex • Fonturacetam [4-phenylpiracetam (carphedon)] • Furfenorex • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane S6.A: NON-SPECIFIED STIMULANTS STIMULANTS 15 S6 Including, but not limited to: • 2-phenylpropan-1-amine (ß-methylphenylethyl- amine, BMPEA) • 3-Methylhexan-2-amine (1,2-dimethylpentylamine) • 4-Fluoromethylphenidate • 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- mine) • 4-Methylpentan-2-amine (1,3-dimethylbutylamine) • 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA) • Benzfetamine • Cathine** • Cathinone and its ana- logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone • Dimetamfetamine (dimethylamphetamine) • Ephedrine*** • Epinephrine**** (adrenaline) • Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydrafinil (fluorenol) • Hydroxyamfetamine (parahydroxyamphet- amine) • Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham- phetamine • Methylephedrine*** • Methylnaphthidate [(±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate] • Methylphenidate • Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl- hexylamine) • Octopamine • Oxilofrine (methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine (methylenedioxyamphet- amine) • Tuaminoheptane * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2024 Monitoring Program and are not considered Prohibited Substances. ** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. S6.B: SPECIFIED STIMULANTS • Clonidine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2024 Monitoring Program*. and other substances with a similar chemical structure or similar biological effect(s). STIMULANTS (continued) EXCEPTIONS 16 S7 • Buprenorphine • Dextromoramide • Diamorphine (heroin) • Fentanyl and its derivatives • Hydromorphone • Methadone • Morphine • Nicomorphine • Oxycodone • Oxymorphone • Pentazocine • Pethidine • Tramadol The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) NARCOTICS 17 S8 All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) • Cannabidiol CANNABINOIDS EXCEPTIONS 18 S9 All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort • Dexamethasone • Flunisolide • Fluocortolone • Fluticasone • Hydrocortisone • Methylprednisolone • Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. GLUCOCORTICOIDS • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. NOTE 19 P1 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol • Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol • Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol • Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol *Also prohibited Out-of-Competition PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances. BETA-BLOCKERS 20 INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 15 1-Androstenediol, 5 1-Androstenedione, 5 1-Androsterone, 5 1-Epiandrosterone, 5 1-Testosterone, 5 1,2-Dimethylpentylamine, 15 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5 1,3-Dimethylamylamine (1,3 DMAA), 15 1,3-Dimethylbutylamine, 15 1,4-Dimethylamylamine (1,4-DMAA), 15 1,4-Dimethylpentylamine, 15 1,5- Dimethyl-hexylamine, 15 2-Androstenol, 10 2-Androstenone, 10 2-Phenylpropan-1-amine, 15 2,4-Dinitrophenol (DNP), 4 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 3ß-Hydroxyandrost-5-en-17-one, 6 3-Androstenol, 10 3-Androstenone, 10 3-Methylhexan-2-amine, 15 4-Androstene-3,6,17 trione, 10 4-Androstenediol, 5 4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 4-Fluoromethylphenidate, 15 4-Hydroxytestosterone, 5 4-Methylhexan-2-amine, 15 4-Methylpentan-2-amine, 15 4-Phenylpiracetam, 14 4,17ß-Dihydroxyandrost-4-en-3-one, 5 5ɑ-Androst-1-ene-3, 17-dione, 5 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 5ɑ-Androst-2-en-17-ol, 10 5ɑ-Androst-2-en-17-one, 10 5ɑ-Androst-3-en-17-ol, 10 5ɑ-Androst-3-en-17-one, 10 5ɑ-Dihydrotestosterone, 5 5-Androstenedione, 5 5-Methylhexan-2-amine, 15 6-Oxo, 10 7ɑ-Hydroxy-DHEA, 5 7ɑ,11ß-Dimethyl-19-nortestosterone, 5 7ɑ-Methyl-19-nortestosterone, 6 7ß-Hydroxy-DHEA, 5 7-Keto-DHEA, 5 11ß-Methyl-19-nortestosterone, 5 11-Ketoandrostenedione, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 17ɑ-Methylepithiostanol, 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 17ß-Hydroxy-5ɑ-androstan-3-one, 5 17ß-Hydroxy-5ß-androstan-3-one, 5 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6 17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6 17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6 17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6 19-Norandrostenediol, 5 19-Norandrostenedione, 5 19-Norpregna-4-en-17ɑ-ol, 5 19-Nortestosterone, 6 ɑ-Pyrrolidinovalerophenone, 15 ß-Methylphenylethylamine, 15 A ACE-031, 11 Acebutolol, 19 Acetazolamide, 12 Activators of the AMP-activated protein kinase (AMPK), 11 Activin A-neutralizing antibodies, 11 Activin receptor IIB competitors, 11 Adrafinil, 14 Adrenaline, 15 Adrenosterone, 5 AICAR, 11 Albumin, 12 Alexamorelin, 8 Alprenolol, 19 Amfepramone, 14 Amfetamine, 14 Amfetaminil, 14 Amiloride, 12 Aminoglutethimide, 10 Amiphenazole, 14 AMP-activated protein kinase (AMPK), 11 Anamorelin, 8 Anastrozole, 10 Andarine, 6 Androst-4-ene-3ß,17ß-diol, 5 Androst-4-ene-3,11,17- trione, 5 Androst-4-ene-3,17-dione, 5 Androst-5-ene-3ß,17ß-diol, 5 Androst-5-ene-3,17-dione, 5 Androsta-1,4,6-triene-3,17-dione, 10 Androsta-1,4-diene-3,17-dione, 5 Androsta-3,5-diene-7,17-dione, 10 Androstanolone, 5 Androstatrienedione, 10 Androstenediol, 5 Androstenedione, 5 Anti-activin receptor IIB antibodies, 11 AOD-9604, 8 Apitegromab, 11 Arformoterol, 9 Arimistane, 10 Asialo EPO, 7 Atenolol, 19 B Bazedoxifene, 10 Beclometasone, 18 Bendroflumethiazide, 12 Benfluorex, 14 Benzfetamine, 15 Benzylpiperazine, 14 Betamethasone, 18 Betaxolol, 19 Bimagrumab, 11 Bisoprolol, 19 Blood, 13 Blood (autologous), 13 Blood (components), 13 Blood (heterologous), 13 Blood (homologous), 13 Blood manipulation, 13 BMPEA, 15 Bolasterone, 5 21 INDEX Boldenone, 5 Boldione, 5 BPC-157, 4 Brimonidine, 15 Brinzolamide, 12 Bromantan, 14 Budesonide, 18 Bumetanide, 12 Bunolol, 19 Buprenorphine, 16 Bupropion, 15 Buserelin, 8 C Caffeine, 15 Calusterone, 5 Cannabidiol, 17 Cannabis, 17 Canrenone, 12 Capromorelin, 8 Carbamylated EPO (CEPO), 7 Carphedon, 14 Carteolol, 19 Carvedilol, 19 Cathine, 12, 15 Cathinone, 15 Celiprolol, 19 Cell (doping), 13 Cell (genetically modified), 13 Cell (normal), 13 Cell (red blood), 13 Chlorothiazide, 12 Chlortalidone, 12 Chorionic Gonadotrophin (CG), 8 Ciclesonide, 18 CJC-1293, 8 CJC-1295, 8 Clenbuterol, 6 Clobenzorex, 14 Clomifene, 10 Clonazoline, 15 Clonidine, 15 Clostebol, 5 CNTO-530, 7 Cobalt, 7 Cocaine, 14 Conivaptan, 12 Corticorelin, 8 Corticotrophins, 8 Cortisone, 18 Cropropamide, 14 Crotetamide, 14 Cyclofenil, 10 D Danazol, 5 Daprodustat, 7 Darbepoetins (dEPO), 7 Deflazacort, 18 Dehydrochlormethyltestosterone, 5 Dehydroepiandrosterone (DHEA), 6 Deslorelin, 8 Desmopressin, 12 Desoxymethyltestosterone, 5 Dexamethasone, 18 Dextran, 12 Dextromoramide, 16 Diamorphine, 16 Dimetamfetamine, 15 Dimethandrolone, 5 Dimethylamphetamine, 15 Domagrozumab, 11 Dorzolamide, 12 Drospirenone, 12 Drostanolone, 5 E Ecstasy, 14 Efaproxiral (RSR13), 13 Enobosarm, 6 Ephedrine, 12, 15 Epiandrosterone, 5 Epi-dihydrotestosterone, 5 Epinephrine, 15 Epistane, 5 Epitestosterone, 5 EPO-based constructs, 7 EPO-Fc, 7 EPO-mimetic agents, 7 Erythropoietin receptor agonists, 7 Erythropoietins (EPO), 7 Esmolol, 19 Estr-4-ene-3,17-diol, 5 Estr-4-ene-3,17-dione, 5 Etacrynic acid, 12 Etamivan, 15 Ethylestrenol, 5 Ethylphenidate, 15 Etilamfetamine, 15 Etilefrine, 15 Examorelin, 8 Exemestane, 10 F Famprofazone, 15 Felypressin, 12 Fenbutrazate, 15 Fencamfamin, 15 Fencamine, 14 Fenetylline, 14 Fenfluramine, 14 Fenoterol, 9 Fenoxazoline, 15 Fenproporex, 14 Fentanyl, 16 Fibroblast growth factors (FGFs), 8 Flunisolide, 18 Fluocortolone, 18 Fluorenol, 15 Fluoxymesterone, 5 Fluticasone, 18 Follistatin, 11 Fonturacetam, 14 Formebolone, 5 Formestane, 10 Formoterol, 9, 12 Fulvestrant, 10 Furazabol, 5 Furfenorex, 14 Furosemide, 12 G GATA inhibitors, 7 Gene doping, 13 Gene editing, 13 Gene silencing, 13 Gene transfer, 13 Gestrinone, 6 Ghrelin, 8 GH-releasing peptides (GHRPs), 8 Gonadorelin, 8 Gonadotrophin-releasing hormone (GnRH), 8 Goserelin, 8 Growth hormone (GH), 8 Growth hormone secretagogues (GHS), 8 GW1516, 11 22 INDEX GW501516, 11 H Haemoglobin (products), 13 Haemoglobin (based blood substitutes), 13 Haemoglobin (microencapsulated products), 13 Hashish, 17 Hepatocyte growth factor (HGF), 8 Heptaminol, 15 Heroin, 16 Hexarelin, 8 hGH 176-191, 8 Higenamine, 9 Histrelin, 8 Hydrafinil, 15 Hydrochlorothiazide, 12 Hydrocortisone, 18 Hydromorphone, 16 Hydroxyamfetamine, 15 Hydroxyethyl starch, 12 Hypoxia-inducible factor (HIF) activating agents, 7 I Ibutamoren, 8 Imidazoline, 15 Indacaterol, 9 Indanazoline, 15 Indapamide, 12 Infusions, 13 Injections (> 100 mL), 13 Innate repair receptor agonists, 7 Insulin-like growth factor-1 (IGF-1), 8 Insulin-mimetics, 11 Insulins, 11 Intravenous infusions/injections, 13 IOX2, 7 Ipamorelin, 8 Isometheptene, 15 K K-11706, 7 Kisspeptin, 8 L Labetalol, 19 Landogrozumab, 11 Lenomorelin, 8 Letrozole, 10 Leuprorelin, 8 Levmetamfetamine, 15 Levosalbutamol, 9 LGD-4033, 6 Ligandrol, 6 Lisdexamfetamine, 14 Lonapegsomatropin, 8 Luspatercept, 7 Luteinizing hormone (LH), 8 M Macimorelin, 8 Mannitol, 12 Marijuana, 17 Mecasermin, 8 Mechano growth factors (MGFs), 8 Meclofenoxate, 15 Mefenorex, 14 Meldonium, 11 MENT, 6 Mephedrone, 15 Mephentermine, 14 Mesocarb, 14 Mestanolone, 6 Mesterolone, 6 Metamfetamine(d-), 14 Metandienone, 6 Metenolone, 6 Methadone, 16 Methandriol, 6 Methasterone, 6 Methedrone, 15 Methoxy polyethylene glycol-epoetin beta (CERA), 7 Methyl-1-testosterone, 6 Methylclostebol, 6 Methyldienolone, 6 Methylenedioxyamphetamine, 15 Methylenedioxymethamphetamine, 15 Methylephedrine, 12, 15 Methylhexaneamine, 15 Methylnaphtidate, 15 Methylnortestosterone, 6 Methylphenidate, 15 Methylprednisolone, 18 Methylsynephrine, 15 Methyltestosterone, 6 Methyltrienolone, 6 Metipranolol, 19 Metolazone, 12 Metoprolol, 19 Metribolone, 6 Mibolerone, 6 MK-677, 8 Modafinil, 14 Molidustat, 7 Mometasone, 18 Morphine, 16 Mozavaptan, 12 Myostatin inhibitors, 11 Myostatin precursor-neutralizing antibodies, 11 Myostatin propeptide, 11 Myostatin-binding proteins, 11 Myostatin-neutralizing antibodies, 11 N Nadolol, 19 Nafarelin, 8 Nandrolone, 6 Naphazoline, 15 Nebivolol, 19 Nicomorphine, 16 Nicotine, 15 Nikethamide, 15 Norboletone, 6 Norclostebol, 6 Norethandrolone, 6 Norfenefrine, 15 Norfenfluramine, 14 Nucleic acids, 13 Nucleic acid analogues, 13 O Octodrine, 15 Octopamine, 15 Olodaterol, 9 Osilodrostat, 6 Ospemifene, 10 Ostarine, 6 Oxabolone, 6 Oxandrolone, 6 Oxilofrine, 15 Oxprenolol, 19 Oxycodone, 16 Oxymesterone, 6 Oxymetazoline, 15 Oxymetholone, 6 Oxymorphone, 16 23 INDEX P Pamabrom, 12 Parahydroxyamphetamine, 15 Peginesatide, 7 Pemoline, 15 Pentazocine, 16 Pentetrazol, 15 Perfluorochemicals, 13 Peroxisome proliferator activated receptor delta agonists, 11 Pethidine, 16 Phendimetrazine, 14 Phenethylamine, 15 Phenmetrazine, 15 Phenpromethamine, 15 Phentermine, 14 Phenylephrine, 15 Phenylpropanolamine, 15 Pindolol, 19 Pipadrol, 15 Plasma expanders, 12 Plasmapheresis, 13 Platelet-derived growth factor (PDGF), 8 p-methylamfetamine, 14 Pralmorelin, 8 Prasterone, 6 Prednisolone, 18 Prednisone, 18 Prenylamine, 14 Probenecid, 12 Procaterol, 9 Prolintane, 14 Propranolol, 19 Propylhexedrine, 15 Prostanozol, 6 Proteases, 13 Pseudoephedrine, 12, 15 Q Quinbolone, 6 R RAD140, 6 Ractopamine, 6 Raloxifene, 10 Reldesemtiv, 4 Reproterol, 9 Rev-erbɑ agonists, 11 Roxadustat, 7 S S-23, 6 Salbutamol, 9, 12 Salmeterol, 9 Selective androgen receptor modulators (SARMs), 6 Selegiline, 15 Sermorelin, 8 Sibutramine, 15 Solriamfetol, 15 Somapacitan, 8 Somatrogon, 8 Sotalol, 19 Sotatercept, 7 Spironolactone, 12 SR9009, 11 SR9011, 11 Stamulumab, 11 Stanozolol, 6 Stenbolone, 6 Strychnine, 15 Synephrine, 15 T Tabimorelin, 8 Tamoxifen, 10 Tampering, 13 TB-500, 8 Tenamfetamine, 15 Terbutaline, 9 Tesamorelin, 8 Testolactone, 10 Testosterone, 6 Testosterone-stimulating peptides 8 Tetracosactide, 8 Tetrahydrocannabinols, 17 Tetrahydrogestrinone, 6 Tetryzoline, 15 Thiazides, 12 Thymosin-ß4, 8 Tibolone, 6 Timolol, 19 Tirasemtiv, 4 Tolvaptan, 12 Torasemide, 12 Toremifene, 10 Tramadol, 16 Tramazoline, 15 Transforming growth factor beta (TGF-ß) signalling inhibitors, 7 Trenbolone, 6 Trestolone, 6 Tretoquinol, 9 Triamcinolone acetonide, 18 Triamterene, 12 Trimetazidine, 11 Trimetoquinol, 9 Triptorelin, 8 Troponin activators, 4 Tuaminoheptane, 15 Tulobuterol, 9 V Vadadustat (AKB-6548), 7 Vaptans, 12 Vascular endothelial growth factor (VEGF), 8 Vilanterol, 9 Voxelotor, 13 X Xenon, 7 Xylometazoline, 15 Y YK-11, 6 Z Zeranol, 6 Zilpaterol, 6 www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2024 This List shall come into effect on 1 January 2024. https://www.wada-ama.org/en 2 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents................................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics............7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists.................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators...................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods............................................................................................. 13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants........................................................................................................................................... 14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics............................................................................................................................................. 16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries. S8 Cannabinoids.................................................................................................................................... 17 S9 Glucocorticoids............................................................................................................................... 18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers................................................................................................................................... 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX...................................................................................................................................................................20 TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. 3 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2024. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC). THE 2024 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2024 Published by: World Anti-Doping Agency Stock Exchange Tower 800 Place Victoria (Suite 1700) PO Box 120 Montreal, Quebec Canada H4Z 1B7 URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: code@wada-ama.org 4 S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157, 2,4- Dinitrophenol (DNP) and Troponin Activators (e.g. Reldesemtiv and Tirasemtiv). PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. NON-APPROVED SUBSTANCES 5 • 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-Hydroxy-DHEA • 7ß-Hydroxy-DHEA • 7-Keto-DHEA • 11ß-Methyl-19-nortestosterone • 17ɑ-Methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro- 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol) • Dimethandrolone (7ɑ,11ß-Dimethyl-19- nortestosterone) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- 17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) Anabolic agents are prohibited. When administered exogenously, including but not limited to: S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 6 S1 • Gestrinone • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl- 5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ- methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ- methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy- 17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a- homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) • Trestolone (7ɑ-Methyl-19-nortestosterone, MENT) and other substances with a similar chemical structure or similar biological effect(s). S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) S1.2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. ANABOLIC AGENTS (continued) 7 S2 Including, but not limited to: S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 8 Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued) S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG), • luteinizing hormone (LH), • gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6] S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS 9 S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Fenoterol • Formoterol • Higenamine • Indacaterol • Levosalbutamol • Olodaterol • Procaterol • Reproterol • Salbutamol • Salmeterol • Terbutaline • Tretoquinol (trimetoquinol) • Tulobuterol • Vilanterol The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. NOTE • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours. EXCEPTIONS BETA-2 AGONISTS 10 S4 The following hormone and metabolic modulators are prohibited. Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone S4.1. AROMATASE INHIBITORS Including, but not limited to: • Bazedoxifene • Clomifene • Cyclofenil • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. HORMONE AND METABOLIC MODULATORS 11 Including, but not limited to: • Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab) S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION S4.4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio) phenoxy) acetic acid (GW1516, GW501516) and Rev-erbɑ agonists, e.g. SR9009, SR9011 S4.4.2 Insulins and insulin-mimetics S4.4.3 Meldonium S4.4.4 Trimetazidine S4.4. METABOLIC MODULATORS S4 HORMONE AND METABOLIC MODULATORS (continued) 12 S5 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan; • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol; • Desmopressin; • Probenecid; and other substances with a similar chemical structure or similar biological effect(s). DIURETICS AND MASKING AGENTS The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. NOTE • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. EXCEPTIONS 13 PROHIBITED METHODS The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system except donation by Athletes of plasma or plasma components by plasmapheresis performed in a registered collection center. M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M2. CHEMICAL AND PHYSICAL MANIPULATION The following, with the potential to enhance sport performance, are prohibited: M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. M3.2. The use of normal or genetically modified cells. M3. GENE AND CELL DOPING PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. 14 S6 All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. A stimulant not expressly listed in this section is a Specified Substance. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) Stimulants include: • Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex • Fonturacetam [4-phenylpiracetam (carphedon)] • Furfenorex • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane S6.A: NON-SPECIFIED STIMULANTS STIMULANTS 15 S6 Including, but not limited to: • 2-phenylpropan-1-amine (ß-methylphenylethyl- amine, BMPEA) • 3-Methylhexan-2-amine (1,2-dimethylpentylamine) • 4-Fluoromethylphenidate • 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- mine) • 4-Methylpentan-2-amine (1,3-dimethylbutylamine) • 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA) • Benzfetamine • Cathine** • Cathinone and its ana- logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone • Dimetamfetamine (dimethylamphetamine) • Ephedrine*** • Epinephrine**** (adrenaline) • Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydrafinil (fluorenol) • Hydroxyamfetamine (parahydroxyamphet- amine) • Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham- phetamine • Methylephedrine*** • Methylnaphthidate [(±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate] • Methylphenidate • Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl- hexylamine) • Octopamine • Oxilofrine (methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine (methylenedioxyamphet- amine) • Tuaminoheptane * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2024 Monitoring Program and are not considered Prohibited Substances. ** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. S6.B: SPECIFIED STIMULANTS • Clonidine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2024 Monitoring Program*. and other substances with a similar chemical structure or similar biological effect(s). STIMULANTS (continued) EXCEPTIONS 16 S7 • Buprenorphine • Dextromoramide • Diamorphine (heroin) • Fentanyl and its derivatives • Hydromorphone • Methadone • Morphine • Nicomorphine • Oxycodone • Oxymorphone • Pentazocine • Pethidine • Tramadol The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) NARCOTICS 17 S8 All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) • Cannabidiol CANNABINOIDS EXCEPTIONS 18 S9 All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort • Dexamethasone • Flunisolide • Fluocortolone • Fluticasone • Hydrocortisone • Methylprednisolone • Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. GLUCOCORTICOIDS • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. NOTE 19 P1 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol • Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol • Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol • Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol *Also prohibited Out-of-Competition PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances. BETA-BLOCKERS 20 INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 15 1-Androstenediol, 5 1-Androstenedione, 5 1-Androsterone, 5 1-Epiandrosterone, 5 1-Testosterone, 5 1,2-Dimethylpentylamine, 15 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5 1,3-Dimethylamylamine (1,3 DMAA), 15 1,3-Dimethylbutylamine, 15 1,4-Dimethylamylamine (1,4-DMAA), 15 1,4-Dimethylpentylamine, 15 1,5- Dimethyl-hexylamine, 15 2-Androstenol, 10 2-Androstenone, 10 2-Phenylpropan-1-amine, 15 2,4-Dinitrophenol (DNP), 4 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 3ß-Hydroxyandrost-5-en-17-one, 6 3-Androstenol, 10 3-Androstenone, 10 3-Methylhexan-2-amine, 15 4-Androstene-3,6,17 trione, 10 4-Androstenediol, 5 4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 4-Fluoromethylphenidate, 15 4-Hydroxytestosterone, 5 4-Methylhexan-2-amine, 15 4-Methylpentan-2-amine, 15 4-Phenylpiracetam, 14 4,17ß-Dihydroxyandrost-4-en-3-one, 5 5ɑ-Androst-1-ene-3, 17-dione, 5 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 5ɑ-Androst-2-en-17-ol, 10 5ɑ-Androst-2-en-17-one, 10 5ɑ-Androst-3-en-17-ol, 10 5ɑ-Androst-3-en-17-one, 10 5ɑ-Dihydrotestosterone, 5 5-Androstenedione, 5 5-Methylhexan-2-amine, 15 6-Oxo, 10 7ɑ-Hydroxy-DHEA, 5 7ɑ,11ß-Dimethyl-19-nortestosterone, 5 7ɑ-Methyl-19-nortestosterone, 6 7ß-Hydroxy-DHEA, 5 7-Keto-DHEA, 5 11ß-Methyl-19-nortestosterone, 5 11-Ketoandrostenedione, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 17ɑ-Methylepithiostanol, 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 17ß-Hydroxy-5ɑ-androstan-3-one, 5 17ß-Hydroxy-5ß-androstan-3-one, 5 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6 17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6 17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6 17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6 19-Norandrostenediol, 5 19-Norandrostenedione, 5 19-Norpregna-4-en-17ɑ-ol, 5 19-Nortestosterone, 6 ɑ-Pyrrolidinovalerophenone, 15 ß-Methylphenylethylamine, 15 A ACE-031, 11 Acebutolol, 19 Acetazolamide, 12 Activators of the AMP-activated protein kinase (AMPK), 11 Activin A-neutralizing antibodies, 11 Activin receptor IIB competitors, 11 Adrafinil, 14 Adrenaline, 15 Adrenosterone, 5 AICAR, 11 Albumin, 12 Alexamorelin, 8 Alprenolol, 19 Amfepramone, 14 Amfetamine, 14 Amfetaminil, 14 Amiloride, 12 Aminoglutethimide, 10 Amiphenazole, 14 AMP-activated protein kinase (AMPK), 11 Anamorelin, 8 Anastrozole, 10 Andarine, 6 Androst-4-ene-3ß,17ß-diol, 5 Androst-4-ene-3,11,17- trione, 5 Androst-4-ene-3,17-dione, 5 Androst-5-ene-3ß,17ß-diol, 5 Androst-5-ene-3,17-dione, 5 Androsta-1,4,6-triene-3,17-dione, 10 Androsta-1,4-diene-3,17-dione, 5 Androsta-3,5-diene-7,17-dione, 10 Androstanolone, 5 Androstatrienedione, 10 Androstenediol, 5 Androstenedione, 5 Anti-activin receptor IIB antibodies, 11 AOD-9604, 8 Apitegromab, 11 Arformoterol, 9 Arimistane, 10 Asialo EPO, 7 Atenolol, 19 B Bazedoxifene, 10 Beclometasone, 18 Bendroflumethiazide, 12 Benfluorex, 14 Benzfetamine, 15 Benzylpiperazine, 14 Betamethasone, 18 Betaxolol, 19 Bimagrumab, 11 Bisoprolol, 19 Blood, 13 Blood (autologous), 13 Blood (components), 13 Blood (heterologous), 13 Blood (homologous), 13 Blood manipulation, 13 BMPEA, 15 Bolasterone, 5 21 INDEX Boldenone, 5 Boldione, 5 BPC-157, 4 Brimonidine, 15 Brinzolamide, 12 Bromantan, 14 Budesonide, 18 Bumetanide, 12 Bunolol, 19 Buprenorphine, 16 Bupropion, 15 Buserelin, 8 C Caffeine, 15 Calusterone, 5 Cannabidiol, 17 Cannabis, 17 Canrenone, 12 Capromorelin, 8 Carbamylated EPO (CEPO), 7 Carphedon, 14 Carteolol, 19 Carvedilol, 19 Cathine, 12, 15 Cathinone, 15 Celiprolol, 19 Cell (doping), 13 Cell (genetically modified), 13 Cell (normal), 13 Cell (red blood), 13 Chlorothiazide, 12 Chlortalidone, 12 Chorionic Gonadotrophin (CG), 8 Ciclesonide, 18 CJC-1293, 8 CJC-1295, 8 Clenbuterol, 6 Clobenzorex, 14 Clomifene, 10 Clonazoline, 15 Clonidine, 15 Clostebol, 5 CNTO-530, 7 Cobalt, 7 Cocaine, 14 Conivaptan, 12 Corticorelin, 8 Corticotrophins, 8 Cortisone, 18 Cropropamide, 14 Crotetamide, 14 Cyclofenil, 10 D Danazol, 5 Daprodustat, 7 Darbepoetins (dEPO), 7 Deflazacort, 18 Dehydrochlormethyltestosterone, 5 Dehydroepiandrosterone (DHEA), 6 Deslorelin, 8 Desmopressin, 12 Desoxymethyltestosterone, 5 Dexamethasone, 18 Dextran, 12 Dextromoramide, 16 Diamorphine, 16 Dimetamfetamine, 15 Dimethandrolone, 5 Dimethylamphetamine, 15 Domagrozumab, 11 Dorzolamide, 12 Drospirenone, 12 Drostanolone, 5 E Ecstasy, 14 Efaproxiral (RSR13), 13 Enobosarm, 6 Ephedrine, 12, 15 Epiandrosterone, 5 Epi-dihydrotestosterone, 5 Epinephrine, 15 Epistane, 5 Epitestosterone, 5 EPO-based constructs, 7 EPO-Fc, 7 EPO-mimetic agents, 7 Erythropoietin receptor agonists, 7 Erythropoietins (EPO), 7 Esmolol, 19 Estr-4-ene-3,17-diol, 5 Estr-4-ene-3,17-dione, 5 Etacrynic acid, 12 Etamivan, 15 Ethylestrenol, 5 Ethylphenidate, 15 Etilamfetamine, 15 Etilefrine, 15 Examorelin, 8 Exemestane, 10 F Famprofazone, 15 Felypressin, 12 Fenbutrazate, 15 Fencamfamin, 15 Fencamine, 14 Fenetylline, 14 Fenfluramine, 14 Fenoterol, 9 Fenoxazoline, 15 Fenproporex, 14 Fentanyl, 16 Fibroblast growth factors (FGFs), 8 Flunisolide, 18 Fluocortolone, 18 Fluorenol, 15 Fluoxymesterone, 5 Fluticasone, 18 Follistatin, 11 Fonturacetam, 14 Formebolone, 5 Formestane, 10 Formoterol, 9, 12 Fulvestrant, 10 Furazabol, 5 Furfenorex, 14 Furosemide, 12 G GATA inhibitors, 7 Gene doping, 13 Gene editing, 13 Gene silencing, 13 Gene transfer, 13 Gestrinone, 6 Ghrelin, 8 GH-releasing peptides (GHRPs), 8 Gonadorelin, 8 Gonadotrophin-releasing hormone (GnRH), 8 Goserelin, 8 Growth hormone (GH), 8 Growth hormone secretagogues (GHS), 8 GW1516, 11 22 INDEX GW501516, 11 H Haemoglobin (products), 13 Haemoglobin (based blood substitutes), 13 Haemoglobin (microencapsulated products), 13 Hashish, 17 Hepatocyte growth factor (HGF), 8 Heptaminol, 15 Heroin, 16 Hexarelin, 8 hGH 176-191, 8 Higenamine, 9 Histrelin, 8 Hydrafinil, 15 Hydrochlorothiazide, 12 Hydrocortisone, 18 Hydromorphone, 16 Hydroxyamfetamine, 15 Hydroxyethyl starch, 12 Hypoxia-inducible factor (HIF) activating agents, 7 I Ibutamoren, 8 Imidazoline, 15 Indacaterol, 9 Indanazoline, 15 Indapamide, 12 Infusions, 13 Injections (> 100 mL), 13 Innate repair receptor agonists, 7 Insulin-like growth factor-1 (IGF-1), 8 Insulin-mimetics, 11 Insulins, 11 Intravenous infusions/injections, 13 IOX2, 7 Ipamorelin, 8 Isometheptene, 15 K K-11706, 7 Kisspeptin, 8 L Labetalol, 19 Landogrozumab, 11 Lenomorelin, 8 Letrozole, 10 Leuprorelin, 8 Levmetamfetamine, 15 Levosalbutamol, 9 LGD-4033, 6 Ligandrol, 6 Lisdexamfetamine, 14 Lonapegsomatropin, 8 Luspatercept, 7 Luteinizing hormone (LH), 8 M Macimorelin, 8 Mannitol, 12 Marijuana, 17 Mecasermin, 8 Mechano growth factors (MGFs), 8 Meclofenoxate, 15 Mefenorex, 14 Meldonium, 11 MENT, 6 Mephedrone, 15 Mephentermine, 14 Mesocarb, 14 Mestanolone, 6 Mesterolone, 6 Metamfetamine(d-), 14 Metandienone, 6 Metenolone, 6 Methadone, 16 Methandriol, 6 Methasterone, 6 Methedrone, 15 Methoxy polyethylene glycol-epoetin beta (CERA), 7 Methyl-1-testosterone, 6 Methylclostebol, 6 Methyldienolone, 6 Methylenedioxyamphetamine, 15 Methylenedioxymethamphetamine, 15 Methylephedrine, 12, 15 Methylhexaneamine, 15 Methylnaphtidate, 15 Methylnortestosterone, 6 Methylphenidate, 15 Methylprednisolone, 18 Methylsynephrine, 15 Methyltestosterone, 6 Methyltrienolone, 6 Metipranolol, 19 Metolazone, 12 Metoprolol, 19 Metribolone, 6 Mibolerone, 6 MK-677, 8 Modafinil, 14 Molidustat, 7 Mometasone, 18 Morphine, 16 Mozavaptan, 12 Myostatin inhibitors, 11 Myostatin precursor-neutralizing antibodies, 11 Myostatin propeptide, 11 Myostatin-binding proteins, 11 Myostatin-neutralizing antibodies, 11 N Nadolol, 19 Nafarelin, 8 Nandrolone, 6 Naphazoline, 15 Nebivolol, 19 Nicomorphine, 16 Nicotine, 15 Nikethamide, 15 Norboletone, 6 Norclostebol, 6 Norethandrolone, 6 Norfenefrine, 15 Norfenfluramine, 14 Nucleic acids, 13 Nucleic acid analogues, 13 O Octodrine, 15 Octopamine, 15 Olodaterol, 9 Osilodrostat, 6 Ospemifene, 10 Ostarine, 6 Oxabolone, 6 Oxandrolone, 6 Oxilofrine, 15 Oxprenolol, 19 Oxycodone, 16 Oxymesterone, 6 Oxymetazoline, 15 Oxymetholone, 6 Oxymorphone, 16 23 INDEX P Pamabrom, 12 Parahydroxyamphetamine, 15 Peginesatide, 7 Pemoline, 15 Pentazocine, 16 Pentetrazol, 15 Perfluorochemicals, 13 Peroxisome proliferator activated receptor delta agonists, 11 Pethidine, 16 Phendimetrazine, 14 Phenethylamine, 15 Phenmetrazine, 15 Phenpromethamine, 15 Phentermine, 14 Phenylephrine, 15 Phenylpropanolamine, 15 Pindolol, 19 Pipadrol, 15 Plasma expanders, 12 Plasmapheresis, 13 Platelet-derived growth factor (PDGF), 8 p-methylamfetamine, 14 Pralmorelin, 8 Prasterone, 6 Prednisolone, 18 Prednisone, 18 Prenylamine, 14 Probenecid, 12 Procaterol, 9 Prolintane, 14 Propranolol, 19 Propylhexedrine, 15 Prostanozol, 6 Proteases, 13 Pseudoephedrine, 12, 15 Q Quinbolone, 6 R RAD140, 6 Ractopamine, 6 Raloxifene, 10 Reldesemtiv, 4 Reproterol, 9 Rev-erbɑ agonists, 11 Roxadustat, 7 S S-23, 6 Salbutamol, 9, 12 Salmeterol, 9 Selective androgen receptor modulators (SARMs), 6 Selegiline, 15 Sermorelin, 8 Sibutramine, 15 Solriamfetol, 15 Somapacitan, 8 Somatrogon, 8 Sotalol, 19 Sotatercept, 7 Spironolactone, 12 SR9009, 11 SR9011, 11 Stamulumab, 11 Stanozolol, 6 Stenbolone, 6 Strychnine, 15 Synephrine, 15 T Tabimorelin, 8 Tamoxifen, 10 Tampering, 13 TB-500, 8 Tenamfetamine, 15 Terbutaline, 9 Tesamorelin, 8 Testolactone, 10 Testosterone, 6 Testosterone-stimulating peptides 8 Tetracosactide, 8 Tetrahydrocannabinols, 17 Tetrahydrogestrinone, 6 Tetryzoline, 15 Thiazides, 12 Thymosin-ß4, 8 Tibolone, 6 Timolol, 19 Tirasemtiv, 4 Tolvaptan, 12 Torasemide, 12 Toremifene, 10 Tramadol, 16 Tramazoline, 15 Transforming growth factor beta (TGF-ß) signalling inhibitors, 7 Trenbolone, 6 Trestolone, 6 Tretoquinol, 9 Triamcinolone acetonide, 18 Triamterene, 12 Trimetazidine, 11 Trimetoquinol, 9 Triptorelin, 8 Troponin activators, 4 Tuaminoheptane, 15 Tulobuterol, 9 V Vadadustat (AKB-6548), 7 Vaptans, 12 Vascular endothelial growth factor (VEGF), 8 Vilanterol, 9 Voxelotor, 13 X Xenon, 7 Xylometazoline, 15 Y YK-11, 6 Z Zeranol, 6 Zilpaterol, 6 www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2026 This List shall come into effect on 1 January 2026. https://www.wada-ama.org/en 2 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents................................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics............7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists.................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators...................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods............................................................................................. 13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants........................................................................................................................................... 15 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics............................................................................................................................................. 17 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries. S8 Cannabinoids.................................................................................................................................... 18 S9 Glucocorticoids............................................................................................................................... 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers..................................................................................................................................20 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX.................................................................................................................................................................... 21 TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. 3 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2026. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC). THE 2026 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2026 Published by: World Anti-Doping Agency Place Victoria, 800, rue du Square-Victoria, bureau 1700 Montréal (Québec) H3C 0B4 Canada URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: code@wada-ama.org 4 S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157, 2,4- dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv). PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. NON-APPROVED SUBSTANCES 5 • 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-Hydroxy-DHEA • 7ß-Hydroxy-DHEA • 7-Keto-DHEA • 11ß-Methyl-19-nortestosterone • 17ɑ-Methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro- 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol) • Dimethandrolone (7ɑ,11ß-Dimethyl-19- nortestosterone) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- 17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) Anabolic agents are prohibited. When administered exogenously, including but not limited to: S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 6 S1 • Gestrinone • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl- 5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ- methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ- methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy- 17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a- homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) • Trestolone (7ɑ-Methyl-19-nortestosterone, MENT) and other substances with a similar chemical structure or similar biological effect(s) including their esters. S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) S1.2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. ANABOLIC AGENTS (continued) 7 S2 Including, but not limited to: S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide, pegmolesatide). S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 8 Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued) S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG) • luteinizing hormone (LH) • gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin) • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6] S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS 9 S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Fenoterol • Formoterol • Higenamine • Indacaterol • Levosalbutamol • Olodaterol • Procaterol • Reproterol • Salbutamol • Salmeterol • Terbutaline • Tretoquinol (trimetoquinol) • Tulobuterol • Vilanterol The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. NOTE • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose • Inhaled salmeterol: maximum 200 micrograms over 24 hours in divided doses not to exceed 100 micrograms over 8 hours starting from any dose • Inhaled vilanterol: maximum 25 micrograms over 24 hours EXCEPTIONS BETA-2 AGONISTS 10 S4 The following hormone and metabolic modulators are prohibited. Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 2-Phenylbenzo[h]chromen-4-one (ɑ-naphthoflavone; 7,8-benzoflavone) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone S4.1. AROMATASE INHIBITORS Including, but not limited to: • Bazedoxifene • Clomifene • Cyclofenil • Elacestrant​ • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. HORMONE AND METABOLIC MODULATORS 11 Including, but not limited to: • Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab) S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION S4.4.1 • Activators of the AMP-activated protein kinase (AMPK), e.g. 5-N,6-N-bis(2- fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (BAM15), AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) • Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl- 4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) • Rev-erbɑ agonists, e.g. SR9009, SR9011 S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597 S4.4.3 Meldonium S4.4.4 Trimetazidine S4.4. METABOLIC MODULATORS S4 HORMONE AND METABOLIC MODULATORS (continued) 12 S5 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol • Desmopressin • Probenecid and other substances with a similar chemical structure or similar biological effect(s). DIURETICS AND MASKING AGENTS The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. NOTE • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide) • Local administration of felypressin in dental anaesthesia EXCEPTIONS 13 PROHIBITED METHODS The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. The withdrawal of blood or blood components (including by apheresis), unless performed for 1) analytical purposes including medical tests or Doping Control, or for 2) donation purposes in a collection center accredited by the relevant regulatory authority of the country in which it operates. M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M1.4. The use of re-breathing systems or equipment to deliver carbon monoxide, unless performed as a diagnostic procedure under the supervision of a medical or scientific professional. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M2. CHEMICAL AND PHYSICAL MANIPULATION PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. 14 PROHIBITED METHODS (continued) The following, with the potential to enhance sport performance, are prohibited: M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. M3.2. The use of normal or genetically modified cells or cell components (e.g. nuclei and organelles such as mitochondria and ribosomes). M3. GENE AND CELL DOPING 15 S6 All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. A stimulant not expressly listed in this section is a Specified Substance. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) Stimulants include: • Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex • Fladrafinil (2-[Bis(4-fluorophenyl) methylsulfinyl]-N-hydroxyacetamide) • Flmodafinil (2-[Bis(4-fluorophenyl) methylsulfinyl]acetamide) • Fonturacetam [4-phenylpiracetam (carphedon)] • Furfenorex • Hydrafinil (fluorenol) • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane S6.A: NON-SPECIFIED STIMULANTS STIMULANTS 16 S6 Including, but not limited to: • 2-phenylpropan-1-amine (ß-methylphenylethyl- amine, BMPEA) • 3-Methylhexan-2-amine (1,2-dimethylpentylamine) • 4-Fluoromethylphenidate • 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- mine) • 4-Methylpentan-2-amine (1,3-dimethylbutylamine) • 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA) • Benzfetamine • Cathine** • Cathinone and its ana- logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone • Dimetamfetamine (dimethylamphetamine) • Ephedrine*** • Epinephrine**** (adrenaline) • Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydroxyamfetamine (parahydroxyamphet- amine) • Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham- phetamine • Methylephedrine*** • Methylnaphthidate [(±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate] • Methylphenidate • Midodrine • Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl- hexylamine) • Octopamine • Oxilofrine (methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine (methylenedioxyamphet- amine) • Tesofensine • Tuaminoheptane * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2026 Monitoring Program and are not considered Prohibited Substances. ** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. S6.B: SPECIFIED STIMULANTS • Clonidine, guanfacine • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2026 Monitoring Program* and other substances with a similar chemical structure or similar biological effect(s). STIMULANTS (continued) EXCEPTIONS 17 S7 • Buprenorphine • Dextromoramide • Diamorphine (heroin) • Fentanyl and its derivatives • Hydromorphone • Methadone • Morphine • Nicomorphine • Oxycodone • Oxymorphone • Pentazocine • Pethidine • Tramadol The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) NARCOTICS 18 S8 All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) • Cannabidiol CANNABINOIDS EXCEPTIONS 19 S9 All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort • Dexamethasone • Flunisolide • Fluocortolone • Fluticasone • Hydrocortisone • Methylprednisolone • Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. GLUCOCORTICOIDS • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. NOTE 20 P1 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)* • Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol • Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol • Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol • Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol *Also prohibited Out-of-Competition PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances. BETA-BLOCKERS 21 INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 16 1-Androstenediol, 5 1-Androstenedione, 5 1-Androsterone, 5 1-Epiandrosterone, 5 1-Testosterone, 5 1,2-Dimethylpentylamine, 16 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5 1,3-Dimethylamylamine (1,3 DMAA), 16 1,3-Dimethylbutylamine, 16 1,4-Dimethylamylamine (1,4-DMAA), 16 1,4-Dimethylpentylamine, 16 1,5- Dimethyl-hexylamine, 16 2-Androstenol, 10 2-Androstenone, 10 2-[Bis(4-fluorophenyl)methylsulfinyl] acetamide, 15 2-[Bis(4-fluorophenyl)methylsulfinyl]- N-hydroxyacetamide, 15 2-Phenylbenzo[h]chromen-4-one, 10 2-Phenylpropan-1-amine, 16 2,4-Dinitrophenol (DNP), 4 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 3ß-Hydroxyandrost-5-en-17-one, 6 3-Androstenol, 10 3-Androstenone, 10 3-Methylhexan-2-amine, 16 4-Androstene-3,6,17 trione, 10 4-Androstenediol, 5 4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 4-Fluoromethylphenidate, 16 4-Hydroxytestosterone, 5 4-Methylhexan-2-amine, 16 4-Methylpentan-2-amine, 16 4-Phenylpiracetam, 15 4,17ß-Dihydroxyandrost-4-en-3-one, 5 5ɑ-Androst-1-ene-3, 17-dione, 5 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 5ɑ-Androst-2-en-17-ol, 10 5ɑ-Androst-2-en-17-one, 10 5ɑ-Androst-3-en-17-ol, 10 5ɑ-Androst-3-en-17-one, 10 5ɑ-Dihydrotestosterone, 5 5-Androstenedione, 5 5-Methylhexan-2-amine, 16 5-N,6-N-bis(2-fluorophenyl)-[1,2,5] oxadiazolo[3,4-b]pyrazine-5,6-diamine, 11 6-Oxo, 10 7ɑ-Hydroxy-DHEA, 5 7ɑ,11ß-Dimethyl-19-nortestosterone, 5 7ɑ-Methyl-19-nortestosterone, 6 7ß-Hydroxy-DHEA, 5 7-Keto-DHEA, 5 7,8-Benzoflavone, 10 11ß-Methyl-19-nortestosterone, 5 11-Ketoandrostenedione, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 17ɑ-Methylepithiostanol, 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 17ß-Hydroxy-5ɑ-androstan-3-one, 5 17ß-Hydroxy-5ß-androstan-3-one, 5 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6 17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6 17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6 17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6 19-Norandrostenediol, 5 19-Norandrostenedione, 5 19-Norpregna-4-en-17ɑ-ol, 5 19-Nortestosterone, 6 ɑ-Naphthoflavone, 10 ɑ-Pyrrolidinovalerophenone, 16 ß-Methylphenylethylamine, 16 A ACE-031, 11 Acebutolol, 20 Acetazolamide, 12 Activators of the AMP-activated protein kinase (AMPK), 11 Activin A-neutralizing antibodies, 11 Activin receptor IIB competitors, 11 Adrafinil, 15 Adrenaline, 16 Adrenosterone, 5 AICAR, 11 Albumin, 12 Alexamorelin, 8 Alprenolol, 20 Amfepramone, 15 Amfetamine, 15 Amfetaminil, 15 Amiloride, 12 Aminoglutethimide, 10 Amiphenazole, 15 AMP-activated protein kinase (AMPK), 11 Anamorelin, 8 Anastrozole, 10 Andarine, 6 Androst-4-ene-3ß,17ß-diol, 5 Androst-4-ene-3,11,17- trione, 5 Androst-4-ene-3,17-dione, 5 Androst-5-ene-3ß,17ß-diol, 5 Androst-5-ene-3,17-dione, 5 Androsta-1,4,6-triene-3,17-dione, 10 Androsta-1,4-diene-3,17-dione, 5 Androsta-3,5-diene-7,17-dione, 10 Androstanolone, 5 Androstatrienedione, 10 Androstenediol, 5 Androstenedione, 5 Anti-activin receptor IIB antibodies, 11 AOD-9604, 8 Apheresis, 13 Apitegromab, 11 Arformoterol, 9 Arimistane, 10 ARM210, 4 Asialo EPO, 7 Atenolol, 20 B BAM15, 11 Bazedoxifene, 10 Beclometasone, 19 Bendroflumethiazide, 12 Benfluorex, 15 22 INDEX Benzfetamine, 16 Benzylpiperazine, 15 Betamethasone, 19 Betaxolol, 20 Bimagrumab, 11 Bisoprolol, 20 Blood, 13 Blood (autologous), 13 Blood (components), 13 Blood (heterologous), 13 Blood (homologous), 13 Blood manipulation, 13 Blood withdrawal, 13 BMPEA, 16 Bolasterone, 5 Boldenone, 5 Boldione, 5 BPC-157, 4 Brimonidine, 16 Brinzolamide, 12 Bromantan, 15 Budesonide, 19 Bumetanide, 12 Bunolol, 20 Buprenorphine, 17 Bupropion, 16 Buserelin, 8 C Caffeine, 16 Calusterone, 5 Cannabidiol, 18 Cannabis, 18 Canrenone, 12 Capromorelin, 8 Carbamylated EPO (CEPO), 7 Carbon monoxide, 13 Carphedon, 15 Carteolol, 20 Carvedilol, 20 Cathine, 12, 16 Cathinone, 16 Celiprolol, 20 Cell (doping), 14 Cell (genetically modified), 14 Cell (normal), 14 Cell (red blood), 13 Cell components (nuclei), 14 Cell components (mitochondria), 14 Cell components (ribosomes), 14 Chlorothiazide, 12 Chlortalidone, 12 Chorionic Gonadotrophin (CG), 8 Ciclesonide, 19 CJC-1293, 8 CJC-1295, 8 Clenbuterol, 6 Clobenzorex, 15 Clomifene, 10 Clonazoline, 16 Clonidine, 16 Clostebol, 5 CNTO-530, 7 Cobalt, 7 Cocaine, 15 Conivaptan, 12 Corticorelin, 8 Corticotrophins, 8 Cortisone, 19 Cropropamide, 15 Crotetamide, 15 Cyclofenil, 10 D Danazol, 5 Daprodustat, 7 Darbepoetins (dEPO), 7 Deflazacort, 19 Dehydrochlormethyltestosterone, 5 Dehydroepiandrosterone (DHEA), 6 Deslorelin, 8 Desmopressin, 12 Desoxymethyltestosterone, 5 Dexamethasone, 19 Dextran, 12 Dextromoramide, 17 Diamorphine, 17 Dimetamfetamine, 16 Dimethandrolone, 5 Dimethylamphetamine, 16 Domagrozumab, 11 Dorzolamide, 12 Drospirenone, 12 Drostanolone, 5 E Ecstasy, 15 Efaproxiral (RSR13), 13 Elacestrant, 10 Enobosarm, 6 Ephedrine, 12, 16 Epiandrosterone, 5 Epi-dihydrotestosterone, 5 Epinephrine, 16 Epistane, 5 Epitestosterone, 5 EPO-based constructs, 7 EPO-Fc, 7 EPO-mimetic agents, 7 Erythropoietin receptor agonists, 7 Erythropoietins (EPO), 7 Esmolol, 20 Esters of anabolic androgenic steroids, 6 Estr-4-ene-3,17-diol, 5 Estr-4-ene-3,17-dione, 5 Etacrynic acid, 12 Etamivan, 16 Ethylestrenol, 5 Ethylphenidate, 16 Etilamfetamine, 16 Etilefrine, 16 Examorelin, 8 Exemestane, 10 F Famprofazone, 16 Felypressin, 12 Fenbutrazate, 16 Fencamfamin, 16 Fencamine, 15 Fenetylline, 15 Fenfluramine, 15 Fenoterol, 9 Fenoxazoline, 16 Fenproporex, 15 Fentanyl, 17 Fibroblast growth factors (FGFs), 8 Fladrafinil 15 Flmodafinil 15 Flunisolide, 19 Fluocortolone, 19 Fluorenol, 15 Fluoxymesterone, 5 Fluticasone, 19 23 INDEX Follistatin, 11 Fonturacetam, 15 Formebolone, 5 Formestane, 10 Formoterol, 9, 12 Fulvestrant, 10 Furazabol, 5 Furfenorex, 15 Furosemide, 12 G GATA inhibitors, 7 Gene doping, 14 Gene editing, 14 Gene silencing, 14 Gene transfer, 14 Gestrinone, 6 Ghrelin, 8 GH-releasing peptides (GHRPs), 8 Gonadorelin, 8 Gonadotrophin-releasing hormone (GnRH), 8 Goserelin, 8 Growth hormone (GH), 8 Growth hormone secretagogues (GHS), 8 Guanfacine, 16 GW1516, 11 GW501516, 11 H Haemoglobin (products), 13 Haemoglobin (based blood substitutes), 13 Haemoglobin (microencapsulated products), 13 Hashish, 18 Hepatocyte growth factor (HGF), 8 Heptaminol, 16 Heroin, 17 Hexarelin, 8 hGH 176-191, 8 Higenamine, 9 Histrelin, 8 Hydrafinil, 15 Hydrochlorothiazide, 12 Hydrocortisone, 19 Hydromorphone, 17 Hydroxyamfetamine, 16 Hydroxyethyl starch, 12 Hypoxia-inducible factor (HIF) activating agents, 7 I Ibutamoren, 8 Imidazoline, 16 Indacaterol, 9 Indanazoline, 16 Indapamide, 12 Infusions, 13 Injections (> 100 mL), 13 Innate repair receptor agonists, 7 Insulin-like growth factor-1 (IGF-1), 8 Insulin-mimetics, 11 Insulins, 11 Intravenous infusions/injections, 13 IOX2, 7 Ipamorelin, 8 Isometheptene, 16 K K-11706, 7 Kisspeptin, 8 L Labetalol, 20 Landogrozumab, 11 Lenomorelin, 8 Letrozole, 10 Leuprorelin, 8 Levmetamfetamine, 16 Levosalbutamol, 9 LGD-4033, 6 Ligandrol, 6 Lisdexamfetamine, 15 Lonapegsomatropin, 8 Luspatercept, 7 Luteinizing hormone (LH), 8 M Macimorelin, 8 Mannitol, 12 Marijuana, 18 Mecasermin, 8 Mechano growth factors (MGFs), 8 Meclofenoxate, 16 Mefenorex, 15 Meldonium, 11 MENT, 6 Mephedrone, 16 Mephentermine, 15 Mesocarb, 15 Mestanolone, 6 Mesterolone, 6 Metamfetamine(d-), 15 Metandienone, 6 Metenolone, 6 Methadone, 17 Methandriol, 6 Methasterone, 6 Methedrone, 16 Methoxy polyethylene glycol-epoetin beta (CERA), 7 Methyl-1-testosterone, 6 Methylclostebol, 6 Methyldienolone, 6 Methylenedioxyamphetamine, 16 Methylenedioxymethamphetamine, 16 Methylephedrine, 12, 16 Methylhexaneamine, 16 Methylnaphtidate, 16 Methylnortestosterone, 6 Methylphenidate, 16 Methylprednisolone, 19 Methylsynephrine, 16 Methyltestosterone, 6 Methyltrienolone, 6 Metipranolol, 20 Metolazone, 12 Metoprolol, 20 Metribolone, 6 Mibolerone, 6 Midodrine, 16 Mitochondria, 14 Mitochondrial open reading frame of the 12S rRNA-c, 11 MK-677, 8 Modafinil, 15 Molidustat, 7 Mometasone, 19 Morphine, 17 MOTS-c, 11 Mozavaptan, 12 Myostatin inhibitors, 11 Myostatin precursor-neutralizing antibodies, 11 Myostatin propeptide, 11 Myostatin-binding proteins, 11 24 INDEX Myostatin-neutralizing antibodies, 11 N Nadolol, 20 Nafarelin, 8 Nandrolone, 6 Naphazoline, 16 Nebivolol, 20 Nicomorphine, 17 Nicotine, 16 Nikethamide, 16 Norboletone, 6 Norclostebol, 6 Norethandrolone, 6 Norfenefrine, 16 Norfenfluramine, 15 Nuclei/nucleus, 14 Nucleic acids, 14 Nucleic acid analogues, 14 O Octodrine, 16 Octopamine, 16 Olodaterol, 9 Organelles (e.g. nuclei, mitochondria, ribosomes), 14 Osilodrostat, 6 Ospemifene, 10 Ostarine, 6 Oxabolone, 6 Oxandrolone, 6 Oxilofrine, 16 Oxprenolol, 20 Oxycodone, 17 Oxymesterone, 6 Oxymetazoline, 16 Oxymetholone, 6 Oxymorphone, 17 P Pamabrom, 12 Parahydroxyamphetamine, 16 Peginesatide, 7 Pegmolesatide, 7 Pemoline, 16 Pentazocine, 17 Pentetrazol, 16 Perfluorochemicals, 13 Peroxisome proliferator activated receptor delta agonists, 11 Pethidine, 17 Phendimetrazine, 15 Phenethylamine, 16 Phenmetrazine, 16 Phenpromethamine, 16 Phentermine, 15 Phenylephrine, 16 Phenylpropanolamine, 16 Pindolol, 20 Pipradrol, 16 Plasma expanders, 12 Platelet-derived growth factor (PDGF), 8 p-methylamfetamine, 15 Pralmorelin, 8 Prasterone, 6 Prednisolone, 19 Prednisone, 19 Prenylamine, 15 Probenecid, 12 Procaterol, 9 Prolintane, 15 Propranolol, 20 Propylhexedrine, 16 Prostanozol, 6 Proteases, 13 Pseudoephedrine, 12, 16 Q Quinbolone, 6 R RAD140, 6 Ractopamine, 6 Raloxifene, 10 Reldesemtiv, 4 Reproterol, 9 Rev-erbɑ agonists, 11 Roxadustat, 7 Ryanodine receptor-1-calstabin complex stabilizers, 4 Re-breathing systems or equipment to deliver carbon monoxide, 13 Ribosomes, 14 S S-107, 4 S-23, 6 S48168, 4 S519, 11 S597, 11 Salbutamol, 9, 12 Salmeterol, 9 Selective androgen receptor modulators (SARMs), 6 Selegiline, 16 Sermorelin, 8 Sibutramine, 16 Solriamfetol, 16 Somapacitan, 8 Somatrogon, 8 Sotalol, 20 Sotatercept, 7 Spironolactone, 12 SR9009, 11 SR9011, 11 Stamulumab, 11 Stanozolol, 6 Stenbolone, 6 Strychnine, 16 Synephrine, 16 T Tabimorelin, 8 Tamoxifen, 10 Tampering, 13 TB-500, 8 Tenamfetamine, 16 Terbutaline, 9 Tesamorelin, 8 Tesofensine, 16 Testolactone, 10 Testosterone, 6 Testosterone-stimulating peptides 8 Tetracosactide, 8 Tetrahydrocannabinols, 18 Tetrahydrogestrinone, 6 Tetryzoline, 16 Thiazides, 12 Thymosin-ß4, 8 Tibolone, 6 Timolol, 20 Tirasemtiv, 4 Tolvaptan, 12 Torasemide, 12 Toremifene, 10 Tramadol, 17 Tramazoline, 16 25 INDEX Transforming growth factor beta (TGF-ß) signalling inhibitors, 7 Trenbolone, 6 Trestolone, 6 Tretoquinol, 9 Triamcinolone acetonide, 19 Triamterene, 12 Trimetazidine, 11 Trimetoquinol, 9 Triptorelin, 8 Troponin activators, 4 Tuaminoheptane, 16 Tulobuterol, 9 V Vadadustat (AKB-6548), 7 Vaptans, 12 Vascular endothelial growth factor (VEGF), 8 Vilanterol, 9 Voxelotor, 13 X Xenon, 7 Xipamide, 12 Xylometazoline, 16 Y YK-11, 6 Z Zeranol, 6 Zilpaterol, 6 www.wada-ama.org https://www.wada-ama.org/en www.wada-ama.org www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2025 This List shall come into effect on 1 January 2025. https://www.wada-ama.org/en 2 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents................................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics............7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists.................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators...................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods............................................................................................. 13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants........................................................................................................................................... 14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics............................................................................................................................................. 16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries. S8 Cannabinoids.................................................................................................................................... 17 S9 Glucocorticoids............................................................................................................................... 18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers................................................................................................................................... 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX...................................................................................................................................................................20 TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. 3 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2025. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC). THE 2025 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2025 Published by: World Anti-Doping Agency Place Victoria, 800, rue du Square-Victoria, bureau 1700 Montréal (Québec) H3C 0B4 Canada URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: code@wada-ama.org 4 S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157, 2,4- dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv). PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. NON-APPROVED SUBSTANCES 5 • 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-Hydroxy-DHEA • 7ß-Hydroxy-DHEA • 7-Keto-DHEA • 11ß-Methyl-19-nortestosterone • 17ɑ-Methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro- 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol) • Dimethandrolone (7ɑ,11ß-Dimethyl-19- nortestosterone) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- 17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) Anabolic agents are prohibited. When administered exogenously, including but not limited to: S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 6 S1 • Gestrinone • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl- 5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ- methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ- methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy- 17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a- homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) • Trestolone (7ɑ-Methyl-19-nortestosterone, MENT) and other substances with a similar chemical structure or similar biological effect(s). S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) S1.2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. ANABOLIC AGENTS (continued) 7 S2 Including, but not limited to: S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 8 Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued) S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG), • luteinizing hormone (LH), • gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6] S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS 9 S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Fenoterol • Formoterol • Higenamine • Indacaterol • Levosalbutamol • Olodaterol • Procaterol • Reproterol • Salbutamol • Salmeterol • Terbutaline • Tretoquinol (trimetoquinol) • Tulobuterol • Vilanterol The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. NOTE • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose; • Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours. EXCEPTIONS BETA-2 AGONISTS 10 S4 The following hormone and metabolic modulators are prohibited. Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone S4.1. AROMATASE INHIBITORS Including, but not limited to: • Bazedoxifene • Clomifene • Cyclofenil • Elacestrant​ • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. HORMONE AND METABOLIC MODULATORS 11 Including, but not limited to: • Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab) S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION S4.4.1 • Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c); • Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl- 4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) and; • Rev-erbɑ agonists, e.g. SR9009, SR9011 S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597 S4.4.3 Meldonium S4.4.4 Trimetazidine S4.4. METABOLIC MODULATORS S4 HORMONE AND METABOLIC MODULATORS (continued) 12 S5 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide; • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan; • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol; • Desmopressin; • Probenecid; and other substances with a similar chemical structure or similar biological effect(s). DIURETICS AND MASKING AGENTS The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. NOTE • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. EXCEPTIONS 13 PROHIBITED METHODS The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M2. CHEMICAL AND PHYSICAL MANIPULATION The following, with the potential to enhance sport performance, are prohibited: M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. M3.2. The use of normal or genetically modified cells. M3. GENE AND CELL DOPING PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. Donation of blood or blood components, including by apheresis, is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates. NOTE 14 S6 All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. A stimulant not expressly listed in this section is a Specified Substance. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) Stimulants include: • Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex • Fonturacetam [4-phenylpiracetam (carphedon)] • Furfenorex • Hydrafinil (fluorenol) • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane S6.A: NON-SPECIFIED STIMULANTS STIMULANTS 15 S6 Including, but not limited to: • 2-phenylpropan-1-amine (ß-methylphenylethyl- amine, BMPEA) • 3-Methylhexan-2-amine (1,2-dimethylpentylamine) • 4-Fluoromethylphenidate • 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- mine) • 4-Methylpentan-2-amine (1,3-dimethylbutylamine) • 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA) • Benzfetamine • Cathine** • Cathinone and its ana- logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone • Dimetamfetamine (dimethylamphetamine) • Ephedrine*** • Epinephrine**** (adrenaline) • Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydroxyamfetamine (parahydroxyamphet- amine) • Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham- phetamine • Methylephedrine*** • Methylnaphthidate [(±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate] • Methylphenidate • Midodrine • Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl- hexylamine) • Octopamine • Oxilofrine (methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine (methylenedioxyamphet- amine) • Tesofensine • Tuaminoheptane * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2025 Monitoring Program and are not considered Prohibited Substances. ** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. S6.B: SPECIFIED STIMULANTS • Clonidine, guanfacine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2025 Monitoring Program*. and other substances with a similar chemical structure or similar biological effect(s). STIMULANTS (continued) EXCEPTIONS 16 S7 • Buprenorphine • Dextromoramide • Diamorphine (heroin) • Fentanyl and its derivatives • Hydromorphone • Methadone • Morphine • Nicomorphine • Oxycodone • Oxymorphone • Pentazocine • Pethidine • Tramadol The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) NARCOTICS 17 S8 All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) • Cannabidiol CANNABINOIDS EXCEPTIONS 18 S9 All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort • Dexamethasone • Flunisolide • Fluocortolone • Fluticasone • Hydrocortisone • Methylprednisolone • Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. GLUCOCORTICOIDS • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. NOTE 19 P1 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)* • Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol • Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol • Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol • Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol *Also prohibited Out-of-Competition PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances. BETA-BLOCKERS 20 INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 15 1-Androstenediol, 5 1-Androstenedione, 5 1-Androsterone, 5 1-Epiandrosterone, 5 1-Testosterone, 5 1,2-Dimethylpentylamine, 15 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5 1,3-Dimethylamylamine (1,3 DMAA), 15 1,3-Dimethylbutylamine, 15 1,4-Dimethylamylamine (1,4-DMAA), 15 1,4-Dimethylpentylamine, 15 1,5- Dimethyl-hexylamine, 15 2-Androstenol, 10 2-Androstenone, 10 2-Phenylpropan-1-amine, 15 2,4-Dinitrophenol (DNP), 4 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 3ß-Hydroxyandrost-5-en-17-one, 6 3-Androstenol, 10 3-Androstenone, 10 3-Methylhexan-2-amine, 15 4-Androstene-3,6,17 trione, 10 4-Androstenediol, 5 4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 4-Fluoromethylphenidate, 15 4-Hydroxytestosterone, 5 4-Methylhexan-2-amine, 15 4-Methylpentan-2-amine, 15 4-Phenylpiracetam, 14 4,17ß-Dihydroxyandrost-4-en-3-one, 5 5ɑ-Androst-1-ene-3, 17-dione, 5 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 5ɑ-Androst-2-en-17-ol, 10 5ɑ-Androst-2-en-17-one, 10 5ɑ-Androst-3-en-17-ol, 10 5ɑ-Androst-3-en-17-one, 10 5ɑ-Dihydrotestosterone, 5 5-Androstenedione, 5 5-Methylhexan-2-amine, 15 6-Oxo, 10 7ɑ-Hydroxy-DHEA, 5 7ɑ,11ß-Dimethyl-19-nortestosterone, 5 7ɑ-Methyl-19-nortestosterone, 6 7ß-Hydroxy-DHEA, 5 7-Keto-DHEA, 5 11ß-Methyl-19-nortestosterone, 5 11-Ketoandrostenedione, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 17ɑ-Methylepithiostanol, 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 17ß-Hydroxy-5ɑ-androstan-3-one, 5 17ß-Hydroxy-5ß-androstan-3-one, 5 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6 17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6 17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6 17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6 19-Norandrostenediol, 5 19-Norandrostenedione, 5 19-Norpregna-4-en-17ɑ-ol, 5 19-Nortestosterone, 6 ɑ-Pyrrolidinovalerophenone, 15 ß-Methylphenylethylamine, 15 A ACE-031, 11 Acebutolol, 19 Acetazolamide, 12 Activators of the AMP-activated protein kinase (AMPK), 11 Activin A-neutralizing antibodies, 11 Activin receptor IIB competitors, 11 Adrafinil, 14 Adrenaline, 15 Adrenosterone, 5 AICAR, 11 Albumin, 12 Alexamorelin, 8 Alprenolol, 19 Amfepramone, 14 Amfetamine, 14 Amfetaminil, 14 Amiloride, 12 Aminoglutethimide, 10 Amiphenazole, 14 AMP-activated protein kinase (AMPK), 11 Anamorelin, 8 Anastrozole, 10 Andarine, 6 Androst-4-ene-3ß,17ß-diol, 5 Androst-4-ene-3,11,17- trione, 5 Androst-4-ene-3,17-dione, 5 Androst-5-ene-3ß,17ß-diol, 5 Androst-5-ene-3,17-dione, 5 Androsta-1,4,6-triene-3,17-dione, 10 Androsta-1,4-diene-3,17-dione, 5 Androsta-3,5-diene-7,17-dione, 10 Androstanolone, 5 Androstatrienedione, 10 Androstenediol, 5 Androstenedione, 5 Anti-activin receptor IIB antibodies, 11 AOD-9604, 8 Apheresis, 13 Apitegromab, 11 Arformoterol, 9 Arimistane, 10 ARM210, 4 Asialo EPO, 7 Atenolol, 19 B Bazedoxifene, 10 Beclometasone, 18 Bendroflumethiazide, 12 Benfluorex, 14 Benzfetamine, 15 Benzylpiperazine, 14 Betamethasone, 18 Betaxolol, 19 Bimagrumab, 11 Bisoprolol, 19 Blood, 13 Blood (autologous), 13 Blood (components), 13 Blood (heterologous), 13 Blood (homologous), 13 Blood manipulation, 13 BMPEA, 15 Bolasterone, 5 21 INDEX Boldenone, 5 Boldione, 5 BPC-157, 4 Brimonidine, 15 Brinzolamide, 12 Bromantan, 14 Budesonide, 18 Bumetanide, 12 Bunolol, 19 Buprenorphine, 16 Bupropion, 15 Buserelin, 8 C Caffeine, 15 Calusterone, 5 Cannabidiol, 17 Cannabis, 17 Canrenone, 12 Capromorelin, 8 Carbamylated EPO (CEPO), 7 Carphedon, 14 Carteolol, 19 Carvedilol, 19 Cathine, 12, 15 Cathinone, 15 Celiprolol, 19 Cell (doping), 13 Cell (genetically modified), 13 Cell (normal), 13 Cell (red blood), 13 Chlorothiazide, 12 Chlortalidone, 12 Chorionic Gonadotrophin (CG), 8 Ciclesonide, 18 CJC-1293, 8 CJC-1295, 8 Clenbuterol, 6 Clobenzorex, 14 Clomifene, 10 Clonazoline, 15 Clonidine, 15 Clostebol, 5 CNTO-530, 7 Cobalt, 7 Cocaine, 14 Conivaptan, 12 Corticorelin, 8 Corticotrophins, 8 Cortisone, 18 Cropropamide, 14 Crotetamide, 14 Cyclofenil, 10 D Danazol, 5 Daprodustat, 7 Darbepoetins (dEPO), 7 Deflazacort, 18 Dehydrochlormethyltestosterone, 5 Dehydroepiandrosterone (DHEA), 6 Deslorelin, 8 Desmopressin, 12 Desoxymethyltestosterone, 5 Dexamethasone, 18 Dextran, 12 Dextromoramide, 16 Diamorphine, 16 Dimetamfetamine, 15 Dimethandrolone, 5 Dimethylamphetamine, 15 Domagrozumab, 11 Dorzolamide, 12 Drospirenone, 12 Drostanolone, 5 E Ecstasy, 14 Efaproxiral (RSR13), 13 Elacestrant, 10 Enobosarm, 6 Ephedrine, 12, 15 Epiandrosterone, 5 Epi-dihydrotestosterone, 5 Epinephrine, 15 Epistane, 5 Epitestosterone, 5 EPO-based constructs, 7 EPO-Fc, 7 EPO-mimetic agents, 7 Erythropoietin receptor agonists, 7 Erythropoietins (EPO), 7 Esmolol, 19 Estr-4-ene-3,17-diol, 5 Estr-4-ene-3,17-dione, 5 Etacrynic acid, 12 Etamivan, 15 Ethylestrenol, 5 Ethylphenidate, 15 Etilamfetamine, 15 Etilefrine, 15 Examorelin, 8 Exemestane, 10 F Famprofazone, 15 Felypressin, 12 Fenbutrazate, 15 Fencamfamin, 15 Fencamine, 14 Fenetylline, 14 Fenfluramine, 14 Fenoterol, 9 Fenoxazoline, 15 Fenproporex, 14 Fentanyl, 16 Fibroblast growth factors (FGFs), 8 Flunisolide, 18 Fluocortolone, 18 Fluorenol, 14 Fluoxymesterone, 5 Fluticasone, 18 Follistatin, 11 Fonturacetam, 14 Formebolone, 5 Formestane, 10 Formoterol, 9, 12 Fulvestrant, 10 Furazabol, 5 Furfenorex, 14 Furosemide, 12 G GATA inhibitors, 7 Gene doping, 13 Gene editing, 13 Gene silencing, 13 Gene transfer, 13 Gestrinone, 6 Ghrelin, 8 GH-releasing peptides (GHRPs), 8 Gonadorelin, 8 Gonadotrophin-releasing hormone (GnRH), 8 Goserelin, 8 Growth hormone (GH), 8 Growth hormone secretagogues (GHS), 8 Guanfacine, 15 GW1516, 11 GW501516, 11 22 INDEX H Haemoglobin (products), 13 Haemoglobin (based blood substitutes), 13 Haemoglobin (microencapsulated products), 13 Hashish, 17 Hepatocyte growth factor (HGF), 8 Heptaminol, 15 Heroin, 16 Hexarelin, 8 hGH 176-191, 8 Higenamine, 9 Histrelin, 8 Hydrafinil, 14 Hydrochlorothiazide, 12 Hydrocortisone, 18 Hydromorphone, 16 Hydroxyamfetamine, 15 Hydroxyethyl starch, 12 Hypoxia-inducible factor (HIF) activating agents, 7 I Ibutamoren, 8 Imidazoline, 15 Indacaterol, 9 Indanazoline, 15 Indapamide, 12 Infusions, 13 Injections (> 100 mL), 13 Innate repair receptor agonists, 7 Insulin-like growth factor-1 (IGF-1), 8 Insulin-mimetics, 11 Insulins, 11 Intravenous infusions/injections, 13 IOX2, 7 Ipamorelin, 8 Isometheptene, 15 K K-11706, 7 Kisspeptin, 8 L Labetalol, 19 Landogrozumab, 11 Lenomorelin, 8 Letrozole, 10 Leuprorelin, 8 Levmetamfetamine, 15 Levosalbutamol, 9 LGD-4033, 6 Ligandrol, 6 Lisdexamfetamine, 14 Lonapegsomatropin, 8 Luspatercept, 7 Luteinizing hormone (LH), 8 M Macimorelin, 8 Mannitol, 12 Marijuana, 17 Mecasermin, 8 Mechano growth factors (MGFs), 8 Meclofenoxate, 15 Mefenorex, 14 Meldonium, 11 MENT, 6 Mephedrone, 15 Mephentermine, 14 Mesocarb, 14 Mestanolone, 6 Mesterolone, 6 Metamfetamine(d-), 14 Metandienone, 6 Metenolone, 6 Methadone, 16 Methandriol, 6 Methasterone, 6 Methedrone, 15 Methoxy polyethylene glycol-epoetin beta (CERA), 7 Methyl-1-testosterone, 6 Methylclostebol, 6 Methyldienolone, 6 Methylenedioxyamphetamine, 15 Methylenedioxymethamphetamine, 15 Methylephedrine, 12, 15 Methylhexaneamine, 15 Methylnaphtidate, 15 Methylnortestosterone, 6 Methylphenidate, 15 Methylprednisolone, 18 Methylsynephrine, 15 Methyltestosterone, 6 Methyltrienolone, 6 Metipranolol, 19 Metolazone, 12 Metoprolol, 19 Metribolone, 6 Mibolerone, 6 Midodrine, 15 Mitochondrial open reading frame of the 12S rRNA-c, 11 MK-677, 8 Modafinil, 14 Molidustat, 7 Mometasone, 18 Morphine, 16 MOTS-c, 11 Mozavaptan, 12 Myostatin inhibitors, 11 Myostatin precursor-neutralizing antibodies, 11 Myostatin propeptide, 11 Myostatin-binding proteins, 11 Myostatin-neutralizing antibodies, 11 N Nadolol, 19 Nafarelin, 8 Nandrolone, 6 Naphazoline, 15 Nebivolol, 19 Nicomorphine, 16 Nicotine, 15 Nikethamide, 15 Norboletone, 6 Norclostebol, 6 Norethandrolone, 6 Norfenefrine, 15 Norfenfluramine, 14 Nucleic acids, 13 Nucleic acid analogues, 13 O Octodrine, 15 Octopamine, 15 Olodaterol, 9 Osilodrostat, 6 Ospemifene, 10 Ostarine, 6 Oxabolone, 6 Oxandrolone, 6 Oxilofrine, 15 Oxprenolol, 19 Oxycodone, 16 Oxymesterone, 6 Oxymetazoline, 15 Oxymetholone, 6 Oxymorphone, 16 23 INDEX P Pamabrom, 12 Parahydroxyamphetamine, 15 Peginesatide, 7 Pemoline, 15 Pentazocine, 16 Pentetrazol, 15 Perfluorochemicals, 13 Peroxisome proliferator activated receptor delta agonists, 11 Pethidine, 16 Phendimetrazine, 14 Phenethylamine, 15 Phenmetrazine, 15 Phenpromethamine, 15 Phentermine, 14 Phenylephrine, 15 Phenylpropanolamine, 15 Pindolol, 19 Pipradrol, 15 Plasma expanders, 12 Platelet-derived growth factor (PDGF), 8 p-methylamfetamine, 14 Pralmorelin, 8 Prasterone, 6 Prednisolone, 18 Prednisone, 18 Prenylamine, 14 Probenecid, 12 Procaterol, 9 Prolintane, 14 Propranolol, 19 Propylhexedrine, 15 Prostanozol, 6 Proteases, 13 Pseudoephedrine, 12, 15 Q Quinbolone, 6 R RAD140, 6 Ractopamine, 6 Raloxifene, 10 Reldesemtiv, 4 Reproterol, 9 Rev-erbɑ agonists, 11 Roxadustat, 7 Ryanodine receptor-1-calstabin complex stabilizers, 4 S S-107, 4 S-23, 6 S48168, 4 S519, 11 S597, 11 Salbutamol, 9, 12 Salmeterol, 9 Selective androgen receptor modulators (SARMs), 6 Selegiline, 15 Sermorelin, 8 Sibutramine, 15 Solriamfetol, 15 Somapacitan, 8 Somatrogon, 8 Sotalol, 19 Sotatercept, 7 Spironolactone, 12 SR9009, 11 SR9011, 11 Stamulumab, 11 Stanozolol, 6 Stenbolone, 6 Strychnine, 15 Synephrine, 15 T Tabimorelin, 8 Tamoxifen, 10 Tampering, 13 TB-500, 8 Tenamfetamine, 15 Terbutaline, 9 Tesamorelin, 8 Tesofensine, 15 Testolactone, 10 Testosterone, 6 Testosterone-stimulating peptides 8 Tetracosactide, 8 Tetrahydrocannabinols, 17 Tetrahydrogestrinone, 6 Tetryzoline, 15 Thiazides, 12 Thymosin-ß4, 8 Tibolone, 6 Timolol, 19 Tirasemtiv, 4 Tolvaptan, 12 Torasemide, 12 Toremifene, 10 Tramadol, 16 Tramazoline, 15 Transforming growth factor beta (TGF-ß) signalling inhibitors, 7 Trenbolone, 6 Trestolone, 6 Tretoquinol, 9 Triamcinolone acetonide, 18 Triamterene, 12 Trimetazidine, 11 Trimetoquinol, 9 Triptorelin, 8 Troponin activators, 4 Tuaminoheptane, 15 Tulobuterol, 9 V Vadadustat (AKB-6548), 7 Vaptans, 12 Vascular endothelial growth factor (VEGF), 8 Vilanterol, 9 Voxelotor, 13 X Xenon, 7 Xipamide, 12 Xylometazoline, 15 Y YK-11, 6 Z Zeranol, 6 Zilpaterol, 6 www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en

1 Summary of Major Modifications and Explanatory Notes 2025 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. Non-Approved Substances • S-107 and S48168 (ARM210) were added to S0 as examples of the class of ryanodine receptor-1-calstabin complex stabilizers. The ryanodine receptor-1-calstabin complex is a major component of calcium storage and release, serving to maintain skeletal muscle function. S3. Beta-2 Agonists • Based on a recent publication1 on potential performance-enhancing doses of inhaled formoterol, the dosing intervals were updated to ensure that ergogenic effects are not achieved. These new 12-hourly dosing intervals are consistent with manufacturers’ recommended use; the maximum delivered dose is unchanged at 54 micrograms over 24 hours. 1 Jeppesen JS, Jessen S,Thomassen M, Backer V, Bangsbo J, Hostrup M. Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists. Scand J Med Sci Sports. 2024;34:e14500.doi:10.1111/sms.14500 2 S5. Diuretics and Masking Agents • Xipamide was added as an example of a diuretic. S4. Hormone and Metabolic Modulators • Elacestrant was added as an example of an anti-estrogen. • Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) was added as an example of an AMP-activated protein kinase activator. • For clarity, S519 and S597 were added as examples of insulin-mimetics. Insulin- mimetics compounds or selective insulin receptor modulators (SIRMs) mimic insulin action by binding to the insulin receptor2. 2 a) Schäffer L, Brissette RE, Spetzler JC, Pillutla RC, Østergaard S, Lennick M, Brandt J, Fletcher PW, Danielsen GM, Hsiao KC, An- dersen AS, Dedova O, Ribel U, Hoeg-Jensen T, Hansen PH, Blume AJ, Markussen J, Goldstein NI. Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4435-9. doi:10.1073/ pnas.0830026100 b) Schäffer L (2006) Pharmaceutically active insulin receptor-modulating molecules. PCT Int Appl WO2006018450 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Donation of blood or blood components (e.g. plasma, red blood cells, white blood cells, platelets and peripheral blood stem cells) including by apheresis is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates. M3. Gene and Cell Doping • Minor editorial change was made for clarity. 4 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES S6. Stimulants • Hydrafinil (fluorenol) was changed from S6.B to S6.A, as this substance is more potent than modafinil and is not licensed for medical use. • Midodrine and tesofensine were added as examples of specified stimulants. • Guanfacine was clarified as not prohibited. PROHIBITED IN PARTICULAR SPORTS P1. Beta-Blockers • Based on information provided by International Ski and Snowboard Federation (FIS), the skiing/snowboarding disciplines of ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air were removed. MONITORING PROGRAM • Fentanyl and tramadol were added to monitor patterns of Out-of-Competition use. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor